<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1350187</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1350187</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hypoxia inducible factor-1&#x251; as a potential therapeutic target for osteosarcoma metastasis</article-title>
<alt-title alt-title-type="left-running-head">Zhou et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1350187">10.3389/fphar.2024.1350187</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Jianghu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2628905/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Lan</surname>
<given-names>Fengjun</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2629540/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Miao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Fengyan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ning</surname>
<given-names>Xu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Hua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sun</surname>
<given-names>Hong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1314974/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Orthopaedics</institution>, <institution>Affiliated Hospital of Guizhou Medical University</institution>, <addr-line>Guiyang</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Orthopaedics</institution>, <institution>West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line>Chengdu</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/978880/overview">Duoyi Zhao</ext-link>, Fourth Affiliated Hospital of China Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2607668/overview">Zou Zhen Wei</ext-link>, Huazhong University of Science and Technology, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1555849/overview">Bing Yang</ext-link>, Tianjin Medical University, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Hong Sun, <email>sunhong002@126.com</email>; Hua Yang, <email>yanghua0203@gmc.edu.cn</email>; Xu Ning, <email>179451982@qq.com</email>
</corresp>
<fn fn-type="equal" id="fn001">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>01</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1350187</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>12</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Zhou, Lan, Liu, Wang, Ning, Yang and Sun.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhou, Lan, Liu, Wang, Ning, Yang and Sun</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Osteosarcoma (OS) is a malignant tumor originating from mesenchymal tissue. Pulmonary metastasis is usually present upon initial diagnosis, and metastasis is the primary factor affecting the poor prognosis of patients with OS. Current research shows that the ability to regulate the cellular microenvironment is essential for preventing the distant metastasis of OS, and anoxic microenvironments are important features of solid tumors. During hypoxia, hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;) expression levels and stability increase. Increased HIF-1&#x3b1; promotes tumor vascular remodeling, epithelial-mesenchymal transformation (EMT), and OS cells invasiveness; this leads to distant metastasis of OS cells. HIF-1&#x3b1; plays an essential role in the mechanisms of OS metastasis. In order to develop precise prognostic indicators and potential therapeutic targets for OS treatment, this review examines the molecular mechanisms of HIF-1&#x3b1; in the distant metastasis of OS cells; the signal transduction pathways mediated by HIF-1&#x3b1; are also discussed.</p>
</abstract>
<kwd-group>
<kwd>osteosarcoma</kwd>
<kwd>HIF-1&#x251;</kwd>
<kwd>metastasis</kwd>
<kwd>cellular microenvironment</kwd>
<kwd>signaling pathways</kwd>
<kwd>therapy</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pharmacology of Anti-Cancer Drugs</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>1 Introduction</title>
<p>Osteosarcoma (OS) is the most common primary bone malignancy, derived from primitive bone-forming mesenchymal cell, for which there are two peak periods of incidence in adolescents and older adults (<xref ref-type="bibr" rid="B117">Shoaib et al., 2022</xref>). OS typically develops near the end of the long bone in the lower limbs, with high local invasiveness, rapid infiltration, and early metastasis (<xref ref-type="bibr" rid="B133">Vailas et al., 2019</xref>; <xref ref-type="bibr" rid="B78">Li K. et al., 2023a</xref>). The pathogenic characteristic of OS, a spindle stromal cell tumor, is the direct conversion of proliferating tumor cells into bone or tissue that resembles bone from the perspective of pathomorphology (<xref ref-type="bibr" rid="B25">Dong et al., 2022</xref>). Histologically, OS encompasses various subtypes including conventional, telangiectatic, small cell, high-grade surface, secondary, low-grade central, periosteal, and parosteal variants. The conventional type of OS (intramedullary high-grade) accounts for approximately 85% of all cases, making it the most prevalent subtype (<xref ref-type="bibr" rid="B109">Rickel et al., 2017</xref>). Neoadjuvant radiotherapy and chemotherapy combined with limb salvage surgery is the primary OS treatment method at present (<xref ref-type="bibr" rid="B5">Anderson, 2016</xref>). In recent years, with the improvement of chemotherapy and the introduction of immunotherapy and targeted therapy, the prognosis and overall survival of OS patients have improved (<xref ref-type="bibr" rid="B154">Yang G. et al., 2021a</xref>). The prognostic survival rate of OS patients with distant metastasis, nevertheless, remains significantly low (<xref ref-type="bibr" rid="B8">Berner et al., 2015</xref>; <xref ref-type="bibr" rid="B10">Bl&#xe4;sius et al., 2022</xref>).</p>
<p>Metastasis means that the cells from an original tumor location invade the surrounding tissue and colonize a new site, through the vascular system or lymphatic duct (<xref ref-type="bibr" rid="B134">Valastyan and Weinberg, 2011</xref>). Metastasis, tumor location, and size are the main factors affecting the poor prognosis of OS, especially metastasis (<xref ref-type="bibr" rid="B119">Smeland et al., 2019</xref>). A significant proportion of individuals diagnosed with OS, ranging from 20%&#x2013;30%, already presented with lung metastases at the time of their initial diagnosis (<xref ref-type="bibr" rid="B16">Chen et al., 2021</xref>). Patients with metastasis at diagnosis or recurrence was only a 20% 5-year survival rate (<xref ref-type="bibr" rid="B96">Meazza and Scanagatta, 2016</xref>). Significantly, recently conducted studies have demonstrated a robust correlation between modifications in the cellular microenvironment and the occurrence of OS metastasis (<xref ref-type="bibr" rid="B62">Jin J. et al., 2023a</xref>).</p>
<p>The tumor cells are experiencing hypoxia as a result of their rapid cellular proliferation, heightened oxygen demand, vascular remodeling, and compromised blood supply (<xref ref-type="bibr" rid="B83">Li Y. et al., 2021a</xref>). The heterogeneity of hypoxia in tumor cells is characterized by varying degrees, ranging from minimal to mild to severe, and the regulatory mechanism varies depending on the degree of hypoxia (<xref ref-type="bibr" rid="B51">Hompland et al., 2021</xref>). Hypoxia-induced modifications in the cellular microenvironment can lead to the activation of multiple signaling pathways (<xref ref-type="bibr" rid="B147">Wu et al., 2023</xref>). The presence of the intricate mechanisms regulating hypoxia undoubtedly presents greater challenges in the treatment of malignancies. It is widely acknowledged that the hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;) is one of the most critical regulators in cellular microenvironment (<xref ref-type="bibr" rid="B58">Ildiz et al., 2023</xref>). The activation of HIF-1&#x3b1; facilitates rapid tumor cell adaptation to hypoxic environments, thereby contributing to the metastasis process of various malignant tumors (<xref ref-type="bibr" rid="B94">Ma et al., 2021</xref>). The regulation of the anoxic microenvironment is also associated with the mechanism of OS metastasis, enabling control over tumor cell invasion and metastasis by manipulating the hypoxic cellular microenvironment to modulate tumor cell heterogeneity (<xref ref-type="bibr" rid="B97">Mohamed et al., 2023</xref>) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Pathological process of distant metastasis of OS. Annotation: The pathological mechanisms of distant metastasis of OS include: Enhance the invasiveness of OS cells; Facilitate the EMT process; Reduce the adhesion ability of OS cells; Enhance the anti-apoptosis characteristics of OS cells; Reconstruction of extracellular environment; Vascular remodeling process of OS cells.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g001.tif"/>
</fig>
<p>In this review, we comprehensively reviewed the molecular mechanisms of HIF-1&#x3b1; in the progression of OS metastasis, alongside the intricate correlation between HIF-1&#x3b1; and the prognosis of patients with metastatic OS as well as relevant therapeutic strategies. Deep insights into the underlying mechanisms implicated in OS metastasis would help improve the prognosis, and provide novel therapeutic targets for patients with metastatic OS.</p>
</sec>
<sec id="s2">
<title>2 Biological characteristics and functions of HIF-1&#x3b1;</title>
<p>The equilibrium of oxygen content in extracellular fluid is crucial for cell survival and normal metabolism (<xref ref-type="bibr" rid="B125">Tao et al., 2021</xref>). Under severe hypoxic stress, cells precisely regulate the expression of certain coding genes or non-coding RNA through oxygen receptors and signal transduction, thereby participating in a variety of physiological and pathological processes (<xref ref-type="bibr" rid="B29">Duan et al., 2024</xref>). The hypoxia-inducible factors are members of the basic helix-loop-helix Per-Arnt-Sim transcription factor superfamily. This heterodimer consists of an oxygen concentration-sensitive HIF-&#x3b1; subunit and a constitutively-expressed HIF-&#x3b2; subunit (<xref ref-type="bibr" rid="B113">Semenza and Wang, 1992</xref>; <xref ref-type="bibr" rid="B139">Wang and Semenza, 1993</xref>). HIF-&#x3b1; subunit includes three subtypes: HIF-1&#x3b1;, HIF-2&#x3b1;, and HIF-3&#x3b1; (<xref ref-type="bibr" rid="B99">Nangaku and Eckardt, 2007</xref>). At present, the role and function of HIF-1&#x3b1; have been extensively studied compared to other subtypes (<xref ref-type="bibr" rid="B107">Ravenna et al., 2016</xref>).</p>
<p>Under normoxic conditions, HIF-1&#x3b1; is unstable, continuously degraded, and maintained at a relatively low basal level (<xref ref-type="bibr" rid="B79">Li L. et al., 2023b</xref>). The prolyl hydroxylase domain (PHD) catalyzes the hydroxylation of proline residues at positions 402 and 564 on the HIF-1&#x3b1; subunit. Hydroxylated HIF-1&#x3b1; is recognized by an E3 ubiquitin ligase complex, that includes the tumor suppressor protein von Hippel-Lindau (VHL), leading to its rapid degradation via the ubiquitin-proteasome pathway. The hydroxylase activity of PHD and HIF-1&#x3b1; is inhibited under hypoxia. After translocation into the nucleus, HIF-1&#x3b1; binds to HIF-1&#x3b2;, forming a transcriptional complex that binds to the hypoxia response element (HRE) in the promoter region of its target gene, which initiates the transcriptional expression of many downstream genes and participates in a variety of physiological and pathological processes (<xref ref-type="bibr" rid="B42">Haase, 2017</xref>). In addition to being regulated by oxygen concentration, HIF-1&#x3b1; is also subject to regulation by various other factors, including the antisense transcription factor aHIF-1&#x3b1;, which has a negative regulatory effect on the transcription of the HIF-1&#x3b1; gene (<xref ref-type="bibr" rid="B9">Bertozzi et al., 2011</xref>). Certain growth factors, inflammatory factors, and oncogenes can also regulate HIF-1&#x3b1; protein stability through signal pathways, such as phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB/AKT) and extracellular regulated protein kinases 1/2 (ERK1/2) (<xref ref-type="bibr" rid="B175">Zhao et al., 2024</xref>). Additionally, multiple miRNAs are also involved in regulating the expression of HIF-1&#x3b1; (<xref ref-type="bibr" rid="B75">Lee et al., 2015</xref>).</p>
<p>Many studies have shown that HIF-1&#x3b1; is implicated in a majority of biological functions, such as promoting angiogenesis, regulating the internal environment, regulating circadian rhythm, inducing autophagy and programmed cell death, and promoting self-renewal and differentiation of mesenchymal stem cells (<xref ref-type="bibr" rid="B1">Adamovich et al., 2017</xref>; <xref ref-type="bibr" rid="B148">Wu et al., 2017</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). The elevated expression level of HIF-1&#x3b1; has been observed in various primary and secondary malignant tumors, making it a valuable biomarker and potential target for clinical diagnosis, targeted treatment, and prognosis evaluation in numerous diseases (<xref ref-type="bibr" rid="B112">Semenza, 2012</xref>; <xref ref-type="bibr" rid="B161">Zeng et al., 2014</xref>; <xref ref-type="bibr" rid="B131">Tuomisto et al., 2016</xref>). Studies also indicated that HIF-1&#x3b1; plays a crucial role in regulating various molecular stages of OS metastasis and demonstrates significant prognostic implications (<xref ref-type="bibr" rid="B69">Khojastehnezhad et al., 2022</xref>). Therefore, HIF-1&#x3b1; may serve as a prognostic indicator for OS metastasis and a potential therapeutic target to enhance the prognosis and survival rate of patients with OS.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The physiological mechanism of HIF-1&#x251; in normoxic and hypoxic environments. Annotation: The mechanism of HIF-1&#x3b1; is different under anoxic and aerobic conditions. Under aerobic condition, HIF-1&#x3b1; cannot exist stably and needs to be degraded through related mechanisms. Under anoxic condition, HIF-1&#x3b1; is activated and participates in the physiological and pathological process of cells through corresponding signal pathways.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g002.tif"/>
</fig>
</sec>
<sec id="s3">
<title>3 Mechanisms of malignant tumor metastasis</title>
<p>The molecular mechanism underlying the initiation and sustenance the metastasis of tumor is intricate (<xref ref-type="bibr" rid="B124">Tanaka and Sakamoto, 2023</xref>). The mechanism encompasses the establishment of a tumor microenvironment, the process of vascular remodeling, the acquisition of tumor cell invasiveness, and the reduction in tumor cell consumption (<xref ref-type="fig" rid="F3">Figure 3</xref>). The initiation and maintenance of the metastatic process in malignant tumor cells involve the coordinated interaction and mutual influence of multiple pathways.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Mechanism of distant Metastasis of malignant tumor. Annotation: The mechanism of distant metastasis in malignant tumors: Firstiy, the enhancement of cell invasiveness, enabling tumor cells to invade surrounding tissues and the vascular system. Subsequently, tumor cells infiltrate the vascular system and surrounding tissues. Immune escape and anti-apoptosis mechanisms within the vasculature while reducing their loss. Finally, host organ microenvironments facilitate tumor cell colonization.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g003.tif"/>
</fig>
<sec id="s3-1">
<title>3.1 Acquisition of cell invasiveness</title>
<p>The acquisition of invasiveness is the primary determinant influencing distant metastasis in tumor cells. As a result of alterations in cellular characteristics, the facilitation of epithelial-mesenchymal transition (EMT), and the disruption of intercellular adhesion, there is an augmentation in the invasive capacity of tumor cells (<xref ref-type="bibr" rid="B162">Zepeda-Enr&#xed;quez et al., 2023</xref>). After the enhancement of the invasive ability of tumor cells, they can invade the vascular system or surrounding tissue through the extracellular matrix (<xref ref-type="bibr" rid="B56">Huang et al., 2020</xref>). EMT is a process of transformation from polarized epithelial cells to mesenchymal cells, which drives tumor progression by enhancing the invasive ability of tumor cells (<xref ref-type="bibr" rid="B54">Huang et al., 2023</xref>). The process of EMT is crucial for facilitating the infiltration of OS cells into the local vascular system and promoting their migration to distant organs (<xref ref-type="bibr" rid="B118">Sinha et al., 2020</xref>). Additionally, the presence of established epithelial phenotypic cells further facilitates the proliferation of secondary tumors in distant organs (<xref ref-type="bibr" rid="B50">Hinton et al., 2023</xref>). Cell adhesion is also an important factors in tumor cell metastasis. Cell adhesion molecules plays a pivotal role in adhesion, triggers intracellular signal transduction, and participates in the regulation of EMT, thereby participating in the progression of distant metastasis of tumor cells (<xref ref-type="bibr" rid="B110">Ruan et al., 2022</xref>).</p>
</sec>
<sec id="s3-2">
<title>3.2 Reduced consumption of tumor cells</title>
<p>Evading immune system monitoring is a crucial process in minimizing tumor cell elimination and facilitating their metastasis (<xref ref-type="bibr" rid="B30">Elanany et al., 2023</xref>). It has been shown that disrupting the tumor vascular system and recruiting aPDL1-loaded platelets can coordinate the response of tumor cells to immune factors and control malignant tumor metastasis (<xref ref-type="bibr" rid="B77">Li H. et al., 2021b</xref>). The anti-apoptosis mechanism enables tumor cell survival in the circulation through the vascular system is another way to reduce the consumption of tumor cells (<xref ref-type="bibr" rid="B181">Zhou et al., 2023</xref>). The presence of the immune escape and anti-apoptosis mechanism can attenuate the consumption of tumor cells during metastasis, giving tumor cells a better chance to travel to and populate the metastatic location.</p>
</sec>
<sec id="s3-3">
<title>3.3 Construction of tumor microenvironment</title>
<p>The establishment of a tumor cell ecological environment involves the coexistence of tumor cells with other tumor cells or host cells within the same microenvironment. From a holistic perspective, the tumor cell environment can be regarded as a complex tumor ecosystem consisting of diverse biological and abiotic factors that interact with each other, and influencing the progression of tumor development through various mechanisms (<xref ref-type="bibr" rid="B12">Bullman, 2023</xref>; <xref ref-type="bibr" rid="B38">Gong et al., 2023</xref>). The initiation of metastasis is accompanied by alterations in the cellular microenvironment, which enables tumor cells to become more invasive (<xref ref-type="bibr" rid="B17">Chen and Song, 2022</xref>). Prior to the infiltration of metastatic tumor cells into the host organ, the coordinated actions of cytokines, exosomes, and metabolites help to create a pre-metastatic milieu in particular organs prior to the entry of metastatic tumor cells and aid circulating tumor cells in completing colonization (<xref ref-type="bibr" rid="B103">Peinado et al., 2017</xref>). Surprisingly, the acidification milieu and elevated extracellular lactate levels also play a vital role in the immunological regulation of tumor cells and the promotion of neovascularization (<xref ref-type="bibr" rid="B39">Gottfried et al., 2006</xref>; <xref ref-type="bibr" rid="B135">V&#xe9;gran et al., 2011</xref>; <xref ref-type="bibr" rid="B11">Brand et al., 2016</xref>; <xref ref-type="bibr" rid="B106">Rastogi et al., 2023</xref>).</p>
</sec>
<sec id="s3-4">
<title>3.4 Vascular remodeling effect</title>
<p>The neovascularization of solid tumors is considered as a pivotal process in the advancement and dissemination of tumors (<xref ref-type="bibr" rid="B70">Kikuchi et al., 2019</xref>). Tumor cells, tumor-associated stromal cells, and their bioactive products collectively contribute to the regulation of angiogenesis within tumor tissues (<xref ref-type="bibr" rid="B22">De Palma et al., 2017</xref>). On vascular remodeling, vascular endothelial growth factor (VEGF) is one of them that has a significant impact (<xref ref-type="bibr" rid="B4">Alsina-Sanchis et al., 2021</xref>). In tumors, the secretion of VEGF is typically continuous, leading to aberrant angiogenesis and structural disarray within the vascular system. As a consequence, tumor tissue hemoperfusion is compromised, along with intercellular junction integrity is missing. This dysfunctional vascular network further facilitates hypoxia and immunosuppression, ultimately fostering tumor progression (<xref ref-type="bibr" rid="B68">Khan and Kerbel, 2018</xref>). In another aspect, the remodeling of tumor vasculature plays a significant role in EMT, cell invasion, cellular infiltration, immunosuppression, and regulation of the cellular microenvironment (<xref ref-type="bibr" rid="B132">Tzeng and Huang, 2023</xref>). Moreover, a remodeled endothelium within capillaries can promote the metastatic colonization of tumor cells (<xref ref-type="bibr" rid="B66">Karreman et al., 2023</xref>).</p>
<p>In brief, the process of tumor cell distant metastasis is a multifaceted and intricate multistage phenomenon, encompassing numerous pivotal steps (<xref ref-type="bibr" rid="B89">Liu QL. et al., 2021a</xref>). Regulation involves multiple factors that interact with each other. Finding significant targets is crucial for exploring the mechanism of OS distant metastasis. The majority of the aforementioned processes are regulated by HIF-1&#x3b1;, which may serve as a crucial hub in controlling OS metastasis.</p>
</sec>
</sec>
<sec id="s4">
<title>4 Molecular mechanisms of HIF-1&#x3b1; in OS</title>
<p>HIF-1&#x3b1;, the most significant regulator of the cellular response to anoxic environments, is associated with OS cell occurrence, development, and treatment resistance (<xref ref-type="bibr" rid="B44">Han and Shen, 2020</xref>). Keratin 17 is a vital component of keratin, and is capable of inducing OS cell development and glycolysis, which are indispensable for cellular energy supply by activating the AKT/mTOR/HIF-1&#x3b1; pathway in the underlying mechanism of OS growth (<xref ref-type="bibr" rid="B152">Yan et al., 2020</xref>). During the process of OS cell proliferation, mitochondrial H<sub>2</sub>O<sub>2</sub> signal transduction promotes tumor cell proliferation through HIF-1&#x3b1;-dependent and HIF-1&#x3b1;-independent manners (<xref ref-type="bibr" rid="B111">Sabharwal et al., 2023</xref>). Another study revealed that HIF-1&#x3b1; and VEGF regulate OS cell apoptosis under hypoxia, and any disruption to one substance may subsequently affect the existence of the other, demonstrating the critical function that HIF-1&#x3b1; and VEGF play in OS apoptosis (<xref ref-type="bibr" rid="B155">Yang SY. et al., 2021b</xref>). Moreover, the mechanism of HIF-1&#x3b1; inducing OS cells growth was confirmed through the urothelial cancer associated 1/protein tyrosine phosphatase/AKT signal pathway (<xref ref-type="bibr" rid="B80">Li T. et al., 2018a</xref>).</p>
<p>Furthermore, there is also a strong association between the expression of HIF-1&#x3b1; and the mechanism of drug resistance in OS cells. Visfatin can enhance miRNA expression through HIF-1&#x3b1;-induced transcription. However, visfatin does not affect zinc finger e-box binding homeobox 1 mRNA expression but significantly increases its protein stability. Decreasing visfatin levels can ameliorate the sensitivity of drug-resistant OS cells to cisplatin (<xref ref-type="bibr" rid="B138">Wang D. et al., 2019a</xref>). HIF-1&#x3b1; is directly targeted by miR-199a, and there is an inverse correlation between miR-199a and HIF-1&#x3b1; mRNA. Overexpression of MiR-199a resensitizes cisplatin resistant OS cells to cisplatin by inhibiting HIF-1&#x3b1; both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B67">Keremu et al., 2019</xref>). The following study presented that miR-216b enhances cisplatin induced apoptosis by regulating the JMJD2C/HIF-1&#x3b1;/Hairy and enhancer of split 1 signal axis in OS cells, which may be a potential strategy for overcoming chemical resistance in OS (<xref ref-type="bibr" rid="B153">Yang et al., 2020</xref>). In another interesting study, transforming growth factor &#x3b2; downregulates the expression of succinate dehydrogenase by reducing the levels of transcription factor STAT1. This leads to upregulation of HIF-1&#x3b1;, which disrupts glucose metabolism and exacerbates chemical resistance in OS cells (<xref ref-type="bibr" rid="B151">Xu et al., 2021</xref>). However, the involvement of HIF-1&#x3b1; extends beyond its role in the occurrence and drug resistance of OS, as it also exhibits a close association with the progression and metastasis of OS (<xref ref-type="bibr" rid="B114">Shang et al., 2022</xref>).</p>
</sec>
<sec id="s5">
<title>5 HIF-1&#x3b1; and the mechanism of OS metastasis</title>
<p>In normoxic and hypoxic environments, HIF-1&#x3b1; exhibits distinct pathological mechanisms and actively participates in molecular mechanism regulation of tumor cells through corresponding signaling pathways (<xref ref-type="bibr" rid="B64">Jin Z. et al., 2023b</xref>; <xref ref-type="bibr" rid="B15">Ceranski et al., 2023</xref>; <xref ref-type="bibr" rid="B82">Li Y. et al., 2023c</xref>; <xref ref-type="bibr" rid="B150">Xie et al., 2023</xref>). Recent studies have shown that HIF-1&#x3b1; genes-related and signal pathways are significantly associated with OS cells metastasis (<xref ref-type="bibr" rid="B173">Zhao et al., 2019</xref>; <xref ref-type="bibr" rid="B46">He G. et al., 2023a</xref>). It can induce and sustain distant metastasis of OS cells by modulating the invasive and metastatic potential of tumor cells, promoting the EMT process, enhancing cellular adhesion, increasing anti-apoptotic properties, inducing immune evasion, facilitating tumor angiogenesis, and fostering microenvironmental remodeling (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The role of HIF-1&#x3b1; signaling pathway in the metastasis mechanism of OS cells.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Classification</th>
<th align="left">Signal pathway</th>
<th align="left">Mechanism</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td rowspan="11" align="left">Invasive potential</td>
<td align="left">CXCR4/HIF-1&#x03B1;</td>
<td align="left">Increases OS cell invasiveness</td>
<td align="left">
<xref ref-type="bibr" rid="B170">Zhang et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">CCL4/HIF-1&#x03B1;/integrin &#x03B1;v&#x03B2;3</td>
<td align="left">Induces cell migration</td>
<td align="left">
<xref ref-type="bibr" rid="B74">Lan et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x03B1;/miR-18b-5p/ PHF2</td>
<td align="left">Increases cell invasion</td>
<td align="left">
<xref ref-type="bibr" rid="B142">Wang et al. (2019b)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x03B1;/NUSAP1</td>
<td align="left">Enhances cell migration and invasion</td>
<td align="left">
<xref ref-type="bibr" rid="B88">Liu et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">GRM4/CBX4/HIF-1&#x03B1;</td>
<td align="left">OS cell proliferation, migration and invasion</td>
<td align="left">
<xref ref-type="bibr" rid="B101">Nieto et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x3b1;/FOXD2-AS1/p21</td>
<td align="left">Increases cell invasiveness</td>
<td align="left">
<xref ref-type="bibr" rid="B146">Wu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">miR-33b/HIF-1&#x3b1;</td>
<td align="left">OS cell proliferation and migration</td>
<td align="left">
<xref ref-type="bibr" rid="B180">Zhou and He (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x3b1;/ANGPTL4</td>
<td align="left">Enhances OS cell proliferation and migration</td>
<td align="left">
<xref ref-type="bibr" rid="B123">Tan and Zhao (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x03B1;/ANGPTL2</td>
<td align="left">Enhances the invasive ability</td>
<td align="left">
<xref ref-type="bibr" rid="B122">Sun et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">miR-20b/HIF-1&#x03B1;/VEGF pathway</td>
<td align="left">OS cell invasion and proliferation</td>
<td align="left">
<xref ref-type="bibr" rid="B127">Th&#x00FC;ring et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">DEC2/HIF-1&#x3b1;</td>
<td align="left">Facilitates OS cells in response to hypoxia; invasion and metastasis</td>
<td align="left">
<xref ref-type="bibr" rid="B115">Shen et al. (2023)</xref>
</td>
</tr>
<tr>
<td rowspan="7" align="left">EMT process</td>
<td align="left">HIF-1&#x3b1;/BNIP3/LC3B</td>
<td align="left">Mitochondrial autophagy</td>
<td align="left">
<xref ref-type="bibr" rid="B108">Ren et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HIF-1&#x3b1;/VEGF</td>
<td align="left">Enhances migration and invasion&#xa0;ability&#xa0;</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Hamidi and Ivaska (2018)</xref>
</td>
</tr>
<tr>
<td align="left">lncRNA NEAT1/miR-186-5p/HIF-1&#x3b1;</td>
<td align="left">Enhances proliferation, invasion, and EMT</td>
<td align="left">
<xref ref-type="bibr" rid="B45">Harjunp&#xe4;&#xe4; et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">SENP1/HIF-1&#x3b1;</td>
<td align="left">Enhances EMT process</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Janiszewska et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">AKT/mTOR/ HIF-1&#x3b1;</td>
<td rowspan="2" align="left">Enhances EMT process</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B76">Leng et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">p38/MAPK/HIF-1&#x3b1;</td>
</tr>
<tr>
<td align="left">HIF-1&#x3b1;/Snail/MMP-9</td>
<td align="left">Enhances EMT process</td>
<td align="left">
<xref ref-type="bibr" rid="B60">Itoh et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">Adhesion ability</td>
<td align="left">MEK/ERK1/2/HIF-1&#x3b1;/ICAM-1</td>
<td align="left">Lung colonization; promotes glycolysis; adhesion</td>
<td align="left">
<xref ref-type="bibr" rid="B32">Feng et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Anti-apoptosis</td>
<td align="left">HIF-1&#x3b1;/FoxO1/Mn SOD/catalase/Sesn3</td>
<td align="left">Promotes cell growth and migration while inhibiting apoptosis</td>
<td align="left">
<xref ref-type="bibr" rid="B169">Zhang et al. (2023)</xref>
</td>
</tr>
<tr>
<td rowspan="3" align="left">Metabolism</td>
<td align="left">HIF-1&#x3b1;/Hsa-circ-0000566/VHLE3</td>
<td align="left">Promotes OS cells glycolysis</td>
<td align="left">
<xref ref-type="bibr" rid="B172">Zhang et al. (2017d)</xref>
</td>
</tr>
<tr>
<td align="left">miR-543/PRMT9/HIF-1&#x3b1;</td>
<td align="left">OS cells glycolysis</td>
<td align="left">
<xref ref-type="bibr" rid="B26">Dou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">MiR-186/ HIF&#x2011;1</td>
<td align="left">Glucose uptake, and lactic acid production in OS cells</td>
<td align="left">
<xref ref-type="bibr" rid="B158">Yu et al. (2019)</xref>
</td>
</tr>
<tr>
<td rowspan="5" align="left">Vascular remodeling</td>
<td align="left">GIT1/ p-ERK/HIF-1&#x3b1;</td>
<td align="left">VEGF release and angiogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B81">Li et al. (2018b)</xref>
</td>
</tr>
<tr>
<td align="left">WISP-1/FAK/JNK/HIF-1&#x3b1;/VEGF-A</td>
<td align="left">Promotes angiogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B145">Watson et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">CCL5/CCR5/PKC/c-Src/HIF-1&#x3b1;</td>
<td align="left">Promotes angiogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B120">Sukumar et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">LncRNA MALAT1/mTOR/HIF-1&#x3b1;</td>
<td align="left">Promotes angiogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B85">Liao et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">LncRNA TUG1/miR-143-5p/HIF-1&#x3b1;</td>
<td align="left">Promotes angiogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B174">Zhao et al. (2015)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s5-1">
<title>5.1 Invasion ability and OS metastasis</title>
<p>Tumor cells possess the capacity for invasion and migration during the early stages of metastasis, enabling them to detach from the primary tumor mass and infiltrate neighboring and distant host tissues (<xref ref-type="bibr" rid="B73">Kushwaha et al., 2019</xref>). The initial phase of metastasis can be completed by HIF-1&#x3b1; by increasing the invasive ability of OS cells (<xref ref-type="fig" rid="F4">Figure 4</xref>). It was established that hBMSC-MVs augment the invasiveness of OS cells under hypoxic conditions through activation of the HIF-1&#x3b1; pathway (<xref ref-type="bibr" rid="B87">Lin et al., 2019</xref>). An intriguing study unveiled a correlation between HIF-1&#x3b1; and C-X-C chemokine receptor type 4 (CXCR4), a chemokine receptor, in the context of OS metastasis. Hypoxia-induced high-metastatic potential OS cells exhibit heightened invasiveness compared to low-metastatic potential counterparts, with their induction being sensitive to CXCR4 antagonists and HIF-1&#x3b1; inhibitors (<xref ref-type="bibr" rid="B40">Guan et al., 2015</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>The molecular mechanism of enhancement invasiveness of OS cells by HIF-1&#x251;. Annotation: HIF-1&#x3b1; is regulated by many factors and regulates the level of downstream target factors, which can enhance the invasive ability of OS cells and increase the risk of distant metastasis.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g004.tif"/>
</fig>
<p>Moreover, OS clinical stage and lung metastasis are positively linked with Chemokine C-C motif ligand 4 (CCL4) and integrin &#x3b1;v&#x3b2;3 expression. CCL4 promotes the development of integrin &#x3b1;v&#x3b2;3 and enhances cell migration potential in OS by activating the HIF-1&#x3b1;, PKB, and focal adhesion kinase (FAK) signaling pathways while suppressing miRNA-3927-3p expression (<xref ref-type="bibr" rid="B129">Tsai et al., 2021</xref>). Hypoxia-induced upregulation of miR-18b-5p through HIF-1&#x3b1; transcriptional control inhibits tumor suppressor gene PHD finger protein 2 (PHF2) expression at the post-transcriptional level; its suggested that the miR-18b-5p-PHF2 signal axis is involved in the HIF-1&#x3b1;-mediated metastasis of OS (<xref ref-type="bibr" rid="B92">Luo et al., 2022</xref>). The upregulation of both HIF-1&#x3b1; and nucleolar and spindle associated protein 1 (NUSAP1) in OS cells positively correlates with their invasive capacity under hypoxic conditions (<xref ref-type="bibr" rid="B165">Zhang et al., 2021</xref>). Although bioinformatics analysis did not show significant differences in glutamate metabotropic receptor 4 (GRM4) expression between OS and normal tissue. However, subsequent cell tests revealed that the interaction between GRM4 and Chromobox 4 had a notable impact on the transcriptional activity of HIF-1&#x3b1;. Overexpressing GRM4 resulted in a substantial reduction in cell proliferation, migration, and invasion ability (<xref ref-type="bibr" rid="B171">Zhang et al., 2020</xref>).</p>
<p>The P21 protein is a cell cycle-dependent protein related to the invasive ability of cells (<xref ref-type="bibr" rid="B13">Cao et al., 2020</xref>). In OS cells, the interaction between FOXD1-AS1 and ZEST homologous enhancer 2 suppresses the level of p21 protein. Simultaneously, the expression of FOXD1AS1 is regulated by the transcription factor HIF-1&#x3b1;, which plays a crucial role in augmenting the malignant biological characteristics of OS cells (<xref ref-type="bibr" rid="B108">Ren et al., 2019</xref>). MiR-33b has been identified as targeting HIF-1&#x3b1;, and its downregulation in OS cells enhances cell proliferation and migration. Overexpression of HIF-1&#x3b1; reverses the inhibitory effect of miR-33b on cell proliferation and migration (<xref ref-type="bibr" rid="B182">Zhou et al., 2017</xref>). Suppressing CircRNA-103801 expression can reduce OS cell proliferation, migration, and invasion capacity. Downregulation of miR-338-3p may lead to upregulation of CircRNA-103801 expression in OS cells through primarily involving the circRNA_103801-miR-338-3p-HIF-1/Rap1/PI3K-Akt pathway; unfortunately, it is not clear which subtype of HIF-1 was involved in this study (<xref ref-type="bibr" rid="B84">Li ZQ. et al., 2021c</xref>).</p>
<p>Angiotensin like 4 (ANGPTL4) is associated with the vascular remodeling and regeneration (<xref ref-type="bibr" rid="B33">Fern&#xe1;ndez-Hernando and Su&#xe1;rez, 2020</xref>). The expression of ANGPTL4 is upregulated by HIF-1&#x3b1; and thus enhances OS cell proliferation and migration (<xref ref-type="bibr" rid="B166">Z et al., 2018</xref>). Quercetin can suppress OS cell migration and invasion in a dose- and time-dependent manner by decreasing HIF-1&#x3b1;, VEGF, matrix metalloproteinase 2 (MMP2) and MMP9 expression (<xref ref-type="bibr" rid="B74">Lan et al., 2017</xref>). It has been indicated that the expression of angiopoietin Like 2 (ANGPTL2) is upregulated in HIF-1&#x3b1;-induced OS cells, and ANGPTL2 overexpression increased OS cells&#x2019; capacity for invasion (<xref ref-type="bibr" rid="B142">Wang X. et al., 2019b</xref>). Meanwhile, miR-20b significantly decreases in OS cells, resulting in overexpression of the target gene HIF-1&#x3b1; and subsequent upregulation of the VEGF pathway. Thereby promoting cell proliferation and invasion (<xref ref-type="bibr" rid="B88">Liu et al., 2016</xref>). Consequently, acquisition of invasive capacity in OS cells trigger the initiation of distant metastasis.</p>
</sec>
<sec id="s5-2">
<title>5.2 EMT and OS cells metastasis</title>
<p>EMT is commonly recognized as a critical step in the development of malignant tumors, characterized by the downregulation of epithelial markers and upregulation of mesenchymal proteins. Consequently, EMT results in the loss of epithelial polarity, relaxation of intercellular junctions, and recombination of cytoskeleton proteins, ultimately facilitating tumor invasion and metastasis (<xref ref-type="bibr" rid="B101">Nieto et al., 2016</xref>). Remarkably, HIF-1&#x3b1; has been demonstrated implicated in regulating the progression of EMT (<xref ref-type="fig" rid="F5">Figure 5</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The molecular mechanism of HIF-1&#x251; in epithelial mesenchymal transformation of OS cells. Annotation: HIF-1 &#x3b1; is involved in the regulation of many factors, which metastasis to the cell matrix, induce the EMT of OS cells and maintain the transformation process.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g005.tif"/>
</fig>
<p>Under hypoxia, the expression of E-cadherin is upregulated, while the expression of Vimentin, N-cadherin, and snail protein is downregulated; all these proteins serve as markers for EMT (<xref ref-type="bibr" rid="B171">Zhang et al., 2020</xref>). With the expression of HIF-1&#x3b1; and TWIST family bHLH transcription factor 1 is upregulated, while the expression of e-cadherin is downregulated, leading to altered EMT process in OS cells (<xref ref-type="bibr" rid="B35">Fujiwara et al., 2020</xref>). Previous studies have reported that HIF-1&#x3b1; can interact with &#x3b2;-catenin to form HIF-1&#x3b1;/&#x3b2;-catenin complex, promoting tumor cell proliferation and metastasis (<xref ref-type="bibr" rid="B146">Wu et al., 2019</xref>). Interestingly, a cellular investigation has revealed a phenomena that defies the foregoing conclusion has been discovered. Their research findings suggested that the regulation of OS cell metastasis involved the mitochondrial autophagy degradation pathway, which was mediated by HIF-1&#x3b1;/BCL2/adenovirus E1B interacting protein 3/light chain 3 beta. The aforementioned mechanism may provide an explanation for the underlying cause of this apparent contradiction (<xref ref-type="bibr" rid="B46">He G. et al., 2023a</xref>). Research has shown significant variations in the expression levels of VEGF, E-cadherin, and N-cadherin in OS cells, corresponding to changes in HIF-1&#x3b1; level, thereby leading to a substantial enhancement in their migratory and invasive capabilities. However, <italic>sauchinone</italic> effectively mitigates the detrimental effects of hypoxia-induced EMT on OS cells (<xref ref-type="bibr" rid="B180">Zhou and He, 2022</xref>). miR-186-5p functions as a downstream target of nuclear enriched abundant transcript 1 which targets HIF-1&#x3b1;. It inhibits proliferation, invasion, and EMT through miR-186-5p/HIF-1&#x3b1; axis in OS cells (<xref ref-type="bibr" rid="B123">Tan and Zhao, 2019</xref>).</p>
<p>In the anoxic microenvironment, both HIF-1&#x3b1; and UMO specific-protease 1 (SENP1) exhibit upregulation in OS cells. Interestingly, inhibition of HIF-1&#x3b1; result in the suppression of SENP1 enhancement. Subsequent inhibition of SENP1 leads to the upregulation of E-cadherin and downregulation of vimentin and N-cadherin, thereby regulating EMT and attenuating the invasive potential of tumor cells (<xref ref-type="bibr" rid="B143">Wang et al., 2018</xref>). <italic>Tetrahydrocurcumin (THC)</italic> reduces HIF-1&#x3b1; levels under hypoxic conditions by blocking the Akt/mTOR and p38/MAPK pathways, thus improving the EMT process (<xref ref-type="bibr" rid="B168">Zhang Y. et al., 2017a</xref>). Another study found that <italic>Melatonin</italic> inhibits EMT in OS cells through HIF-1&#x3b1;/Snail/MMP-9 signal transduction, thereby inhibiting OS metastasis (<xref ref-type="bibr" rid="B18">Chen et al., 2020</xref>). When exposed to hypoxia, silencing of HIF-1&#x3b1; restore the upregulation of E-cadherin expression and downregulates vimentin expression in OS cells, significantly impacting their proliferative and invasive abilities. <italic>Resveratrol</italic> prevented the development of HIF-1&#x3b1; protein without altering HIF-1&#x3b1; mRNA levels (<xref ref-type="bibr" rid="B122">Sun et al., 2015</xref>).</p>
<p>The process of EMT assumes a paramount significance in enabling tumor cells to acquire invasive abilities, thus serving as an essential node in initiating and spreading malignant tumors. The cytokine HIF-1&#x3b1; plays a crucial role in regulating the process of EMT. Therefore, focusing on modulating the HIF-1&#x3b1;-regulated EMT process will offer a novel therapeutic approach for treatment of metastatic OS.</p>
</sec>
<sec id="s5-3">
<title>5.3 Cell adhesion and OS metastasis</title>
<p>Adhesive changes are an important feature of malignant tumors (<xref ref-type="bibr" rid="B91">Liu et al., 2022</xref>; <xref ref-type="bibr" rid="B127">Th&#xfc;ring et al., 2023</xref>). Due to the lack of cellular adhesion, tumor cells possess the capacity to infiltrate neighboring tissues as individual cells or small clusters, thereby enhancing their potential for distant metastasis (<xref ref-type="bibr" rid="B37">Gkretsi and Stylianopoulos, 2018</xref>; <xref ref-type="bibr" rid="B14">Cao et al., 2023</xref>). Cell adhesion encompasses cell-cell, cell-extracellular matrix, and cell-protein interactions (<xref ref-type="bibr" rid="B43">Hamidi and Ivaska, 2018</xref>). Integrin, cadherin, selectin, and IgCAM are the key regulators involved in cell adhesion (<xref ref-type="bibr" rid="B45">Harjunp&#xe4;&#xe4; et al., 2019</xref>). E-cadherin, integrin, and epithelial cell adhesion molecules are closely related to EMT and tumor cell migration; selectin and IgCAM may serve as important factors enabling tumor cells to evade immune surveillance (<xref ref-type="bibr" rid="B61">Janiszewska et al., 2020</xref>). Targeting cell adhesion molecules is a popular approach in antitumor therapy, particularly focusing on inhibiting integrins (<xref ref-type="bibr" rid="B43">Hamidi and Ivaska, 2018</xref>). Surprisingly, the mechanism of cellular adhesion has been elucidated in the dissemination of certain malignant tumors (<xref ref-type="bibr" rid="B76">Leng et al., 2016</xref>). The discovery offers promising prospects for the management of metastatic malignant tumors.</p>
<p>In the mechanism of bone tumor metastasis (<xref ref-type="fig" rid="F6">Figure 6</xref>), intercellular adhesion molecule-1 (ICAM-1) expression is connected to HIF-1&#x3b1;, IL-6 enhances ICAM-1 expression through activation of the MEK/ERK1/2/HIF-1&#x3b1; pathway in OS cells, and Tet methylcytosine dioxygenase 2 contributes to demethylation and IL-6 upregulation in tumor cells (<xref ref-type="bibr" rid="B60">Itoh et al., 2018</xref>). The alteration in the process of EMT, as indicated by the change in cadherin expression, frequently occurs concurrently with loss of cellular adhesion (<xref ref-type="bibr" rid="B3">Almotiri et al., 2021</xref>; <xref ref-type="bibr" rid="B34">Fujisaki and Futaki, 2022</xref>). These findings suggest a potential association between OS cell adhesion, EMT process and OS cells invasiveness.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Molecular mechanism of HIF-1&#x251; receptor in OS cell adhesion, anti-apoptotic properties and matrix environment construction. Annotation: On the one hand, changes in the level of downstream factors regulated by HIF-1&#x3b1; and changes in the cellular matrix environment such as the degradation of reactive oxygen species enhance the ability of cells to resist apoptosis. On the other hand, the downstream factors regulated by HIF-1&#x3b1; participate in the glycolysis process of OS cells, enhance cell adhesion and participate in the construction of a suitable environment for OS cell growth, guide OS cells to break through local lesions, colonization, and complete the process of metastasis.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g006.tif"/>
</fig>
</sec>
<sec id="s5-4">
<title>5.4 Cell apoptosis and OS metastasis</title>
<p>Apoptosis is one of the main pathways of programmed cell death, which can be triggered by multiple extracellular and intracellular factors (<xref ref-type="bibr" rid="B105">Pih&#xe1;n et al., 2017</xref>). Enhanced antiapoptotic properties alter tumor cell characteristics and elevate the risk of distant metastasis events (<xref ref-type="fig" rid="F6">Figure 6</xref>). It has been shown that HIF-1&#x3b1; can directly regulate ForkheadboxClassO1 in OS cells, prevent the accumulation of reactive oxygen species (ROS), and inhibit manganese-dependent superoxide dismutase, catalase, and Sesn3. Hypoxia-induced ROS formation and apoptosis in OS cells are associated with interference in the cytochrome P450 enzyme system. The HIF-1&#x3b1; inhibitor 2-mercaptoethanol and ROS inducer arsenic oxide inhibit OS cell proliferation and migration while promoting apoptosis (<xref ref-type="bibr" rid="B121">Sun et al., 2019</xref>). <italic>In vitro</italic> experiments have confirmed that HIF-1&#x3b1; downregulates caspase-3 expression, promotes OS cell growth, and inhibits apoptosis processes (<xref ref-type="bibr" rid="B93">Lv et al., 2016</xref>).</p>
<p>The transcription factor DEC2 gene is associated with a shortened sleep rhythm and plays a role in regulating tumor pathology as a transcriptional suppressor (<xref ref-type="bibr" rid="B49">He et al., 2009</xref>). It has been demonstrated that DEC2 expression is significantly correlated with HIF-1&#x3b1; levels. In OS cell lines, knockdown of DEC2 reduces HIF-1&#x3b1; accumulation and compromise the ability of HIF-1&#x3b1; to activate its target genes in response to hypoxia. Increased expression of DEC2 causes OS cells to accumulate HIF-1&#x3b1; more quickly, which aids their adaptation to anoxic environments (<xref ref-type="bibr" rid="B53">Hu et al., 2015</xref>). Additionally, the death mechanism of OS cells is supplemented by HIF-1&#x3b1;-induced autophagy. As a result of prolyl hydroxylase being inhibited by ROS and Zn, autophagy is demonstrated to be triggered in OS cells via the connection between HIF-1&#x3b1; and the autophagy-zinc-ROS autophagy cycle axis (<xref ref-type="bibr" rid="B47">He et al., 2020</xref>).</p>
<p>Radiation therapy is a treatment modality employed for the management of malignant tumor cells. The administration of HIF-1&#x3b1; siRNA treatment significantly diminishes the hypoxia-induced antiradiation potential of OS cells (<xref ref-type="bibr" rid="B63">Jin et al., 2015</xref>). Under hypoxic conditions, HIF-1&#x3b1;overexpression expedites ROS clearance through autophagy induction in OS cells, thereby conferring radiation resistance to these cells (<xref ref-type="bibr" rid="B32">Feng et al., 2016</xref>). Targeting the HIF-1&#x3b1; pathway may enhance radiation resistance induced by hypoxia (<xref ref-type="bibr" rid="B137">von et al., 2021</xref>). Anti-apoptotic properties increase the potential of OS distant metastasis. The HIF-1&#x3b1; signaling pathway plays an important role in regulating OS cell apoptosis. Regulating related signal factors in order to promote tumor cell apoptosis allows for new treatments for metastatic OS.</p>
</sec>
<sec id="s5-5">
<title>5.5 Establishment of microenvironment and OS metastasis</title>
<p>Malignant tumors can proliferate rapidly, and the increasing oxygen consumption of tumor cells perpetuates their hypoxic environment. Within this hypoxic milieu, tumor cells obtain energy through glycolysis, i.e., the Warburg effect (<xref ref-type="bibr" rid="B86">Liberti and Locasale, 2016</xref>). Cell metabolism undergoes different stages during distant malignant tumor cell metastasis, providing energy and essential metabolites for the continuous growth and proliferation of cancer cells (<xref ref-type="bibr" rid="B104">Phan et al., 2014</xref>). The metabolic activity of tumor cells fosters an advantageous environment for the biological activities of malignant cells (<xref ref-type="bibr" rid="B169">Zhang et al., 2023</xref>). Simultaneously, through a dynamic multi-step metastasis cascade, the communication between the structural and cellular components within the tumor microenvironment (TME) induces cancer cells to disseminate from their primary site to distant areas (<xref ref-type="bibr" rid="B100">Neophytou et al., 2021</xref>). Following colonization in distant organs, metastatic cells interact with the TME, which involves angiogenesis and other processes, and the metabolic process is reprogrammed to achieve metastatic tumor cell growth (<xref ref-type="bibr" rid="B22">De Palma et al., 2017</xref>; <xref ref-type="bibr" rid="B160">Zanconato et al., 2019</xref>).</p>
<p>In the process of OS metastasis (<xref ref-type="fig" rid="F6">Figure 6</xref>), Hsa-circ-0000566 is regulated by HIF-1&#x3b1;, and both directly binds to VHLE3 ubiquitin ligase protein to inhibit VHL-mediated ubiquitin degradation, thereby promoting their pivotal role in glycolysis of OS cells (<xref ref-type="bibr" rid="B115">Shen et al., 2023</xref>). Mechanistically, protein arginine methyltransferase 9 (PrMT9) exerts control over HIF-1&#x3b1; through a distinct mechanism. miR-543 suppresses oxidative phosphorylation, which is promoted by PrMT9, and deletion of miR-543 enhances the PrMT9-induced destabilization of HIF-1&#x3b1;, leading to inhibition of glycolysis in OS cells (<xref ref-type="bibr" rid="B164">Zhang H. et al., 2017b</xref>). It has been shown that miR-186 regulates the expression of HIF-1&#x3b1; by targeting pituitary tumor transforming gene 1, thus facilitating glucose uptake and promoting lactic acid generation (<xref ref-type="bibr" rid="B149">Xiao et al., 2018</xref>).</p>
<p>The remodeling of the cellular microenvironment, as mentioned in the mechanism of malignant tumor metastasis, not only facilitates the acquisition of invasive ability by tumor cells but also plays a crucial role in sustaining metastasis and facilitating host organ colonization. This substantiates that the TME induced by HIF-1&#x3b1; is related to maintaining the stability of all OS cell metastasis stages, HIF-1&#x3b1; regulation is an important way to inhibit distant OS metastasis.</p>
</sec>
<sec id="s5-6">
<title>5.6 Vascular remodeling and OS metastasis</title>
<p>Vascular remodeling is an important factor that impacts tumor cell growth and metastasis by facilitating oxygen and nutrient supply to the cancer cells, as well as supporting their infiltration and extravasation. Tumor angiogenesis is triggered by environmental stress, with hypoxia being the most significant contributor. Environmental stress leads to the imbalance of promoting/anti-angiogenesis, which leads to increased expression of angiogenic factors (<xref ref-type="bibr" rid="B20">Corre et al., 2020</xref>). Although OS is a highly vascularized bone tumor, the mechanism of neovascularization in OS remains unknown. Studies have shown that HIF-1&#x3b1; plays an important role in vascular remodeling of OS (<xref ref-type="fig" rid="F7">Figure 7</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The roles of HIF-1&#x251; in vascular remodeling of OS cells. Annotation: HIF-1&#x3b1;-induced signal pathway regulates the vascular remodeling process of OS tissue and improves the anoxic environment of OS cells. At the same time, the vascular remodeling process will undoubtedly increase the risk of metastasis of OS cells.</p>
</caption>
<graphic xlink:href="fphar-15-1350187-g007.tif"/>
</fig>
<p>The research findings confirmed that in addition to increasing OS cell invasion capacity, HIF-1&#x3b1; mediates ANGPTL2 expression and promotes VEGF, Angie, and Hexokinase 2 synthesis <italic>in vitro</italic> and <italic>in vivo</italic>. These factors are related to vascular remodeling in OS cells (<xref ref-type="bibr" rid="B142">Wang X. et al., 2019b</xref>). ERK1/2 is a key player in G-protein-coupled receptor interacting protein 1 (GIT1)-mediated VEGF secretion and angiogenesis, while HIF-1&#x3b1; acts as the primary transcription factor controlling VEGF production. Under hypoxia, HIF-1&#x3b1; expression can be observed; however, its deletion by GIT1 drastically reduces its expression by preventing ERK1/2 activation. In such circumstances, although VEGF levels also decrease, the downregulation of HIF-1&#x3b1; expression occurs. Therefore, the researchers hypothesized that the ERK1/2/HIF-1&#x3b1; pathway could be utilized to elucidate this mechanism (<xref ref-type="bibr" rid="B170">Zhang et al., 2018</xref>).</p>
<p>The transcriptional activities of HIF-1&#x3b1; and activator protein-1 (AP-1) are regulated by &#x3b1;-CaMKII. By encouraging the binding of VEGF transcript with HIF-1&#x3b1; and AP-1, VEGF expression is increased, which aids in the neovascularization of OS (<xref ref-type="bibr" rid="B21">Daft et al., 2015</xref>). HIF-1&#x3b1;, FAK, and Jun N-terminal kinase signal pathways are activated upon stimulation of WNT1-induced signal pathway protein-1 (WISP-1). The interaction between integrin and WISP-1 contributes to the control of vascular regulation, increase VEGA production in human OS cells and stimulate angiogenesis and migration in human endothelial progenitor cells (<xref ref-type="bibr" rid="B130">Tsai et al., 2017</xref>). Additionally, HIF-1&#x3b1; gene suppression through siRNA can drastically lower VEGF protein levels and VEGF mRNA expression at the transcriptional level, effectively suppressing angiogenesis (<xref ref-type="bibr" rid="B167">Zhang XD. et al., 2017c</xref>). In previous studies, ribonucleic acid binding protein AUF1 directly binds and stabilizes the positive regulatory factor HIF-1&#x3b1; and VEGF-A gene, and positively regulates the expression of both genes, which enhances the angiogenic ability of OS cells <italic>in vitro</italic> and <italic>in vivo</italic>. This effect is caused by inoculating AUF1 protein into the sequence of VEGF-A and HIF-1&#x3b1; (<xref ref-type="bibr" rid="B2">Al-Khalaf and Aboussekhra, 2019</xref>).</p>
<p>Interestingly, the involvement of THC in the HIF-1&#x3b1;-mediated EMT process is not only evident but also demonstrates a partial inhibitory effect on OS vascular remodeling (<xref ref-type="bibr" rid="B168">Zhang Y. et al., 2017a</xref>). It has been indicated that the HIF-1&#x3b1;-mediated PKC/c-Src/HIF-1&#x3b1; signaling pathway is activated by Cmurc chemokine ligand 5/C-C chemokine receptor 5, leading to an increase in tumor angiogenesis dependent on VEGF in the OS microenvironment (<xref ref-type="bibr" rid="B141">Wang et al., 2015</xref>). In a fascinating study, the involvement of HIF-1&#x3b1; in the regulation of the rapamycin mTOR/HIF-1&#x3b1;/metastasis-related lung adenocarcinoma transcript 1 signaling axis has been confirmed, highlighting its significance in vascular remodeling in OS (<xref ref-type="bibr" rid="B172">Zhang ZC. et al., 2017d</xref>). Subsequent research revealed increased expression of HIF-1&#x3b1;, monocyte chemoattractant protein-1 (MCP1), MCP2, MCP3, Lmur6, and VEGF in OS cells associated with vascular remodeling along the osteosarcoma&#x2019;s metastatic pathway (<xref ref-type="bibr" rid="B26">Dou et al., 2021</xref>). Furthermore, the process of vascular remodeling in OS is regulated by taurine upregulation of gene 1 (TUG1), which is owing to a competitive binding mechanism, TUG1 competitively protected HIF-1&#x3b1; from miR-143-5p, and is expected to be the prognostic indicator and therapeutic target of OS (<xref ref-type="bibr" rid="B158">Yu et al., 2019</xref>).</p>
<p>Another mechanism of vascular remodeling in tumor cell metastasis is tumor cell infiltration and extravasation. During a specific stage of capillary endothelial cell remodeling, cancer cells successfully exudate and form new capillary rings, which is characteristic of invasive malignant tumor metastasis (<xref ref-type="bibr" rid="B36">Giordo et al., 2022</xref>; <xref ref-type="bibr" rid="B66">Karreman et al., 2023</xref>). Unfortunately, limited knowledge exists regarding this pathway in terms of OS metastasis.</p>
<p>Vascular remodeling plays a crucial role in the adaptive development of tumor cells, contributing to the establishment of a metastatic microenvironment for solid tumors (<xref ref-type="bibr" rid="B81">Li X. et al., 2018b</xref>). Inhibition of angiogenesis in solid tumors can induce apoptosis in OS cells; thus, preventing vascular remodeling represents a promising strategy to enhance the prognosis of metastatic OS.</p>
</sec>
<sec id="s5-7">
<title>5.7 Immune escape and OS metastasis</title>
<p>As previously mentioned, the majority of solid tumor cells are in a hypoxic state due to their malignant characteristics. The hypoxia of microenvironment is associated with immune escape and immune cell apoptosis (<xref ref-type="bibr" rid="B136">Vito et al., 2020</xref>). During glycolysis, lactic acid is produced in the extracellular matrix, and increased lactic acid levels can inhibit T cell function and enhance tumor cell anti-immune response (<xref ref-type="bibr" rid="B23">DePeaux and Delgoffe, 2021</xref>; <xref ref-type="bibr" rid="B145">Watson et al., 2021</xref>). Hypoxic metabolism induces an immunosuppressive TME that augments T cell hyperresponsiveness. Specifically, HIF-1&#x3b1; specifically inhibits immune cell function in the TME (<xref ref-type="bibr" rid="B98">Multhoff and Vaupel, 2020</xref>). This enables the tumor to escape immune-mediated killing, thus reducing the efficacy of many immunotherapy methods (<xref ref-type="bibr" rid="B136">Vito et al., 2020</xref>). Conversely, HIF-1&#x3b1; inhibition can enhance T cell anti-tumor activity and inhibit glycolysis, and reducing HIF-1&#x3b1; levels in the TME can increase memory T cell production and improve anti-tumor function (<xref ref-type="bibr" rid="B120">Sukumar et al., 2013</xref>). The aforementioned phenomenon accelerates the metastasis of tumor cells and reduces their consumption involved in the metastatic process (<xref ref-type="bibr" rid="B85">Liao et al., 2020</xref>). Unfortunately, the mechanism of immune evasion in HIF-1&#x3b1;-mediated OS transmission has not been reported and requires further investigation.</p>
</sec>
</sec>
<sec id="s6">
<title>6 Therapeutic prospect of targeting HIF-1&#x3b1; in the treatment of metastatic OS</title>
<p>Metastatic events are crucial factors influencing the unfavorable prognosis in OS, and effective management of metastatic risk holds particular significance for prognosis. It is worth considering that when OS undergoes metastasis, treatment should not solely focus on the primary tumor but also aim to inhibit its invasion and metastasis. This underscores the necessity to comprehend the shared characteristics of primary tumors, tumor metastasis, and secondary sites of metastasis (<xref ref-type="bibr" rid="B28">Du et al., 2023</xref>). Research has showed that HIF-1&#x3b1; participates in nearly all processes involved in OS metastasis and serves as a pivotal target within the respective molecular mechanisms. Modulating HIF-1&#x3b1; levels may potentially achieve inhibition of OS metastasis. Interestingly, COX regression analysis confirmed again that HIF-1&#x3b1; expression is a prognostic indicator for the survival of patients with OS. It promotes OS cell invasion by increasing the production of VEGF, which is a promising therapeutic target for metastatic OS prognosis (<xref ref-type="bibr" rid="B174">Zhao et al., 2015</xref>).</p>
<sec id="s6-1">
<title>6.1 HIF-1&#x3b1; and gene therapy</title>
<p>In targeted gene therapy, HDACIs are traditionally considered as effective tumor inhibitors as their effect via loosening tightly-wound chromatin to inhibit a variety of tumor suppressor genes. bSAHA, an FDA-approved I/IIb/IV HDACI drug, effectively inhibits the nuclear translocation of HIF-1&#x3b1; by directly acetylating Hsp90 and significantly reduces its transcriptional activity (<xref ref-type="bibr" rid="B163">Zhang C. et al., 2017e</xref>). However, it is important to investigate whether SAHA can also inhibit OS metastasis. While current research is limited to autophagy, paclitaxel has demonstrated its ability to target HIF-1&#x3b1; and reduce its activity in OS cells (<xref ref-type="bibr" rid="B41">Guo et al., 2015</xref>). Furthermore, px-478 has been reported to modulate the transcriptional level of HIF-1&#x3b1; (<xref ref-type="bibr" rid="B71">Koh et al., 2008</xref>). Similarly, the compound YC-1 possesses the capacity to inhibit HIF-1&#x3b1;&#x2019;s transcriptional activity and effectively impede protein accumulation (<xref ref-type="bibr" rid="B52">Hu et al., 2020</xref>). A potent inhibitor of HIF-1, echinomycin is a small-molecule antibiotic derived from the bacterium <italic>Streptomyces</italic>. It competitively hinders the function of HIF-1&#x3b1; by binding to the HRE region. Unfortunately, subsequent research revealed its hazardous nature (<xref ref-type="bibr" rid="B59">Infantino et al., 2021</xref>; <xref ref-type="bibr" rid="B175">Zhao et al., 2024</xref>). Currently, the creation of echinococcin liposomes has the potential to improve drug accessibility and safety while reducing tumor growth and metastasis (<xref ref-type="bibr" rid="B7">Bailey et al., 2020</xref>). The aforementioned statement exemplifies the feasibility of developing HIF-1&#x3b1;-targeted inhibitors that exhibit both advantageous and safe effects.</p>
</sec>
<sec id="s6-2">
<title>6.2 HIF-1&#x3b1; and vascular remodeling</title>
<p>Inhibiting tumor vascular remodeling is a crucial approach employed to suppress OS metastasis. VEGF serves as an important target of OS in anti-vascular remodeling, which affects almost every step of metastasis. The therapeutic options for OS anti-angiogenesis encompass VEGF monoclonal antibody (bevacizumab), tyrosine kinase inhibitors (sorafenib, apatinib, pazopanil and rigofinib), and recombinant human endostatin (Endostar) (<xref ref-type="bibr" rid="B90">Liu Y. et al., 2021b</xref>). Interestingly, bevacizumab not only inhibits vascular remodeling but also participates in immune mechanism regulation (<xref ref-type="bibr" rid="B102">Park et al., 2023</xref>). Recent studies have shown that proprietary Chinese medicines can effectively inhibit vascular remodeling in OS. For instance, the synthesis of vancomycin derivative T-methyl chloride can stabilize HIF-1&#x3b1; protein and activate its transcriptional activity, thereby inducing gene expression of downstream targets such as VEGF and GLUT-1 (<xref ref-type="bibr" rid="B95">Magae et al., 2019</xref>). Moreover, curcumin exerts multiple inhibitory effects on OS metastatic cells including cell adhesion and vascular remodeling (<xref ref-type="bibr" rid="B159">Zahedipour et al., 2021</xref>). Therefore, anti-angiogenesis may simultaneously target multiple molecular mechanisms involved in the process of OS metastasis, making it the most promising therapeutic approach for inhibiting OS metastasis.</p>
</sec>
<sec id="s6-3">
<title>6.3 HIF-1&#x3b1; and immunotherapy</title>
<p>Immunotherapy is a novel approach employed in the treatment of OS in recent years, and yielding promising outcomes (<xref ref-type="bibr" rid="B128">Tian et al., 2023</xref>). OS cells are enveloped by a complex immune microenvironment wherein HIF-1&#x3b1; plays a crucial role in regulating immune factors such as interleukins, transforming growth factor, VEGF, and other elements that significantly contribute to OS metastasis. In the OS cell model, immunotherapy has been observed to augment the efficacy of chemotherapeutic drugs to some extent (<xref ref-type="bibr" rid="B140">Wang H. et al., 2023a</xref>; <xref ref-type="bibr" rid="B179">Zhong et al., 2023</xref>). Therefore, modulation of the cellular immune microenvironment assumes paramount importance in the management of metastatic OS (<xref ref-type="bibr" rid="B55">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="B72">Kuo et al., 2023</xref>).</p>
<p>It has been reported that T cells are capable of expressing cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1), which are considered as the primary targets of immune checkpoint inhibitors for tumor cells (<xref ref-type="bibr" rid="B19">Conforti et al., 2018</xref>). The expression of CTLA-4 exhibits a positive correlation with the prognosis of OS, and the expression level of CTLA-4 is related to the signal pathway of PD-1 activation. Administration of CTLA-4 blockers and antagonists has the potential to restore anti-tumor immunity by activating B7 and CD28 signal transduction pathways (<xref ref-type="bibr" rid="B128">Tian et al., 2023</xref>). PD-1 is the key nodes of immune escape of tumor cells, and the expression of PD-1 and its receptor programmed death ligand-1 (PD-L1) is negatively associated with OS prognosis (<xref ref-type="bibr" rid="B178">Zheng et al., 2015</xref>; <xref ref-type="bibr" rid="B156">Yang W. et al., 2021c</xref>). Treatment with PD-1 inhibitors in OS mice model results in a significant reduction in the probability of lung metastasis (<xref ref-type="bibr" rid="B176">Zheng et al., 2018</xref>). Although the role of HIF-1&#x3b1; on PD-1/PD-L1 in OS cells remains unconfirmed, inhibiting the expression of HIF-1&#x3b1; can effectively reduce the expression level of PD-1 in glioma and prostate cancer cells (<xref ref-type="bibr" rid="B24">Ding et al., 2021</xref>; <xref ref-type="bibr" rid="B116">Shen et al., 2022</xref>). Decreased expression of HIF-1&#x3b1; and PD-L1 promotes the infiltration of CD8 T cells, and increases the levels of TNF-&#x3b1;, IFN-&#x3b3;, thereby significantly enhancing the efficacy of anti-PD-1 therapy in gastric cancer cells (<xref ref-type="bibr" rid="B144">Wang Z. et al., 2023b</xref>). Significantly, PD-L1 has been proved to be a downstream target of HIF-1&#x3b1; in hepatocellular carcinoma (<xref ref-type="bibr" rid="B157">Yao et al., 2023</xref>). Interestingly, the HIF-1&#x3b1; inhibitor echinomycin not only augments the therapeutic efficacy of anti-CTLA-4 therapy in immunotherapy, but also enhances the immune tolerance function of PD-1/PD-L1 checkpoints in normal tissues. This dual effects serves to eliminate the immune escape mechanism within the tumor microenvironment, thereby facilitating a safer and more effective approach to immunotherapy (<xref ref-type="bibr" rid="B6">Bailey et al., 2022</xref>). Thus, the immune escape mechanism mediated by HIF-1&#x3b1; may be involved in the metastatic process of OS. More researches are demanded to investigate the potential role of HiF-1a in the immunotherapy of metastatic OS.</p>
</sec>
<sec id="s6-4">
<title>6.4 HIF-1&#x3b1; and ROS level regulation</title>
<p>The level of ROS and the activation of HIF-1&#x3b1; exhibit a significant correlation. The primary focus of research on the regulatory mechanism of HIF-1&#x3b1; lies in elucidating the connection between the HIF-1&#x3b1; pathway and ROS, particularly in terms of modulating environmental ROS levels to maintain optimal HIF-1&#x3b1; expression. N-acetylcysteine is an inhibitor of ROS that can inhibit the apoptosis of diosgenin-related p38/MAPK signal transduction. This indicates that ROS plays an important role in diosgenin-induced apoptosis (<xref ref-type="bibr" rid="B177">Zheng et al., 2023</xref>). In addition, the class I HDAC inhibitor MS-275 enhances the vulnerability of ROS in sarcoma cells. Acetylhistological analysis showed that MS-275 promotes rapid acetylation of lysine RNA binding proteins and blocked the binding and translation activation of NFE2L2 and the corresponding mRNA target HIF-1&#x3b1; to stress granule nucleator G3BP1, thus promoting translation control of key cytoprotective factors and inhibiting the metastatic activity of OS cells (<xref ref-type="bibr" rid="B31">El-Naggar et al., 2019</xref>). Increased ROS levels not only promoted the iron death process of OS cells but were also significantly correlated with cisplatin resistance (<xref ref-type="bibr" rid="B48">He P. et al., 2023b</xref>). D-arginine is the inert metabolic enantiomer of L-arginine, which can produce nitric oxide, enhance oxygen activity in the cell matrix, downregulate HIF-1&#x3b1;, reduce tumor hypoxia, and increase the sensitivity of OS to radiotherapy, as well as enhance the effect of tumor ablation and effectively prevent lung metastasis (<xref ref-type="bibr" rid="B27">Du et al., 2021</xref>).</p>
<p>Gene therapy, immunotherapy and optimization of the cellular microenvironment (including regulation of angiogenesis and ROS concentration) can effectively regulate the level of HIF-1&#x3b1;, which is very important to improve the prognosis of metastatic OS. It is conceivable to develop therapeutic targets or interventions that are both safe and efficient, albeit the research in this domain is still in its nascent stages. This underscores the imperative for conducting a substantial amount of research to establish efficacious and targeted therapy options for successful treatment of metastatic OS.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s7">
<title>7 Conclusion</title>
<p>The development and subsequent metastasis not solely determined by genetic alterations within the tumor cells, but also by the adaptive advantages conferred by these mutations in the particular environment (<xref ref-type="bibr" rid="B126">Tarin, 2013</xref>). Anoxic microenvironment can promote tumor cells invasion and facilitate the formation of a &#x201c;pre-metastatic niche&#x201d; resembling &#x201c;soil&#x201d; in distant organs, which serves as a colonization site for circulating tumor cells and leads to the occurrence of metastatic lesions (<xref ref-type="bibr" rid="B65">Kakkad et al., 2019</xref>; <xref ref-type="bibr" rid="B57">Hussain et al., 2020</xref>). The involvement of HIF-1&#x3b1; in facilitating the rapid adaptation of tumor cells to the anoxic microenvironment and thus plays crucial roles in OS metastasis. During these processes, HIF-1&#x3b1; is engaged in activating several important signaling pathways, including FAK, AKT, PI3K-Akt, VEGF, ERK1/2. These findings of the current study suggest that HIF-1&#x3b1; orchestrates the process of OS metastasis through a highly intricate network, encompassing the initiation, maintenance, and distant colonization of metastatic lesions. For better prediction and treatment for OS metastasis, further investigation into the link between HIF-1&#x3b1; and OS metastasis is imperative.</p>
<p>Targeting HIF-1&#x3b1; as a strategy to reverse the metastatic process in OS demonstrates significant potential; however, current challenges still persist. Recent studies indicate that HIF-1&#x3b1; levels can be modulated through appropriate interventions and the utilization of specific pharmaceutical agents. Therefore, the development of HIF-1&#x3b1; inhibitors is expected to offer more promising therapeutic options for patients with metastatic OS in the future. However, the current understanding of HIF-1&#x3b1; in the tumor microenvironment and its corresponding small-molecule inhibitors is still in the developmental phase, yet to progress to the clinical trial stage. In order to facilitate the clinical application of HIF-1&#x3b1;, it is imperative to determine its efficacy, bioavailability, and potential adverse effects in patients with metastatic OS.</p>
<p>In a word, it can be concluded that HIF-1&#x3b1; promotes the initiation and development of OS metastasis though facilitating cell invasion, vascular remodeling, EMT, and immune escape. Targeting HIF-1&#x3b1; has the potential to decelerate the progression of OS metastasis. Hence, it is essential to elucidate of the precise mechanism underlying HIF-1&#x3b1; in OS metastasis. Moreover, further investigation of associated molecular mechanisms may facilitate the development of efficient and safe small-molecule inhibitors for HIF-1&#x3b1; in treatment of patients of metastatic OS.</p>
</sec>
</body>
<back>
<sec id="s8">
<title>Author contributions</title>
<p>JZ: Data curation, Investigation, Visualization, Writing&#x2013;original draft. FL: Data curation, Software, Visualization, Writing&#x2013;original draft. ML: Formal Analysis, Project administration, Writing&#x2013;review and editing. FW: Project administration, Supervision, Writing&#x2013;review and editing. XN: Conceptualization, Methodology, Supervision, Writing&#x2013;review and editing. HY: Conceptualization, Funding acquisition, Project administration, Resources, Writing&#x2013;review and editing. HS: Conceptualization, Funding acquisition, Resources, Writing&#x2013;review and editing.</p>
</sec>
<sec sec-type="funding-information" id="s9">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The study was funded by the Science and Technology Fund of Guizhou Science and Technology Department (QKH-ZK [2021] 391; QKH-ZK [2023] 344), Science and Technology Fund of Guizhou Provincial Health Commission (gzwjkj 2020-1-120; gzwkj 2021-261), the Youth Fund cultivation program of National Natural Science Foundation of Affiliated Hospital of Guizhou Medical University (gyfynsfc-2021-12), and Graduate Scientific Research Fund project of Guizhou (YJSKYJJ [2021]157).</p>
</sec>
<sec sec-type="COI-statement" id="s10">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12">
<title>Abbreviations</title>
<p>OS, Osteosarcoma; HIF-1&#x3b1;, Hypoxia-inducible factor-1&#x3b1;; PHD, Proly Hydroxylase Domain; VHL, VonHippel-Lindaup; HRE, Hypoxia response element; PI3K, Phosphoinositide 3-Kinase; PKB/AKT, Protein Kinase B; ERK 1/2, Extracellular regulated protein kinases 1/2; EMT, Epithelial-mesenchymal transformation; CCL4, Chemokine C motif ligand 4; FAK, Focal adhesion kinase; GRM4, Glutamate metabotropic receptor 4; CXCR4, C-X-C chemokine receptor type-4; PHF 2, PHD Finger Protein 2; ANGPTL 4, Angiotensin like 4; MMP 2, Matrix metalloproteinase-2; VEGF, Vascular endothelial growth factor; SENP 1, SUMO-specificprotease1; TWIST 1, TWIST family bHLH transcription factor 1; ROS, Reactive oxygen species; TME, Tumor microenvironment; PRMT9, Promotes protein arginine methyltransferases 9; GIT1, G-protein-coupled receptor interacting protein 1; MCP 1, Monocyte chemoattractant protein-1; TUG 1, Taurine upregulated gene 1; ICAM-1, Intercellular adhesion molecule-1; PD-1, Programmed cell death protein 1; CTLA-4, Cytotoxic T lymphocyte-associated antigen-4; PD-L1, Programmed death ligand-1.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamovich</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ladeuix</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Golik</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koeners</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Asher</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Rhythmic oxygen levels reset circadian clocks through HIF1&#x3b1;</article-title>. <source>Cell Metab.</source> <volume>25</volume>, <fpage>93</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.014</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Khalaf</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Aboussekhra</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>AUF1 positively controls angiogenesis through mRNA stabilization-dependent up-regulation of HIF-1&#x3b1; and VEGF-A in human osteosarcoma</article-title>. <source>Oncotarget</source> <volume>10</volume>, <fpage>4868</fpage>&#x2013;<lpage>4879</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.27115</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almotiri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alzahrani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Menendez-Gonzalez</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Abdelfattah</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alotaibi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Saleh</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Zeb1 modulates hematopoietic stem cell fates required for suppressing acute myeloid leukemia</article-title>. <source>J. Clin. Invest.</source> <volume>131</volume>, <fpage>e129115</fpage>. <pub-id pub-id-type="doi">10.1172/JCI129115</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alsina-Sanchis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>M&#xfc;lfarth</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Control of tumor progression by angiocrine factors</article-title>. <source>Cancers (Basel)</source> <volume>13</volume>, <fpage>2610</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13112610</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>M. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Update on survival in osteosarcoma</article-title>. <source>Orthop. Clin. North Am.</source> <volume>47</volume>, <fpage>283</fpage>&#x2013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.ocl.2015.08.022</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Devenport</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Targeting HIF-1&#x3b1; abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues</article-title>. <source>J. Clin. Invest.</source> <volume>132</volume>, <fpage>132</fpage>. <pub-id pub-id-type="doi">10.1172/jci150846</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Liposomal formulation of HIF-1&#x3b1; inhibitor echinomycin eliminates established metastases of triple-negative breast cancer</article-title>. <source>Nanomedicine</source> <volume>29</volume>, <fpage>102278</fpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2020.102278</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Johannesen</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Berner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Haugland</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Bjerkehagen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>B&#xf8;hler</surname>
<given-names>P. J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma</article-title>. <source>Acta Oncol.</source> <volume>54</volume>, <fpage>25</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.3109/0284186X.2014.923934</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertozzi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Iurlaro</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sordet</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Marinello</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zaffaroni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Capranico</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Characterization of novel antisense HIF-1&#x3b1; transcripts in human cancers</article-title>. <source>Cell Cycle</source> <volume>10</volume>, <fpage>3189</fpage>&#x2013;<lpage>3197</lpage>. <pub-id pub-id-type="doi">10.4161/cc.10.18.17183</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bl&#xe4;sius</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Delbr&#xfc;ck</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hildebrand</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hofmann</surname>
<given-names>U. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Surgical treatment of bone sarcoma</article-title>. <source>Cancers (Basel)</source> <volume>14</volume>, <fpage>2694</fpage>. <pub-id pub-id-type="doi">10.3390/cancers14112694</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koehl</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Kolitzus</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schoenhammer</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells</article-title>. <source>Cell Metab.</source> <volume>24</volume>, <fpage>657</fpage>&#x2013;<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.011</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bullman</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The intratumoral microbiota: from microniches to single cells</article-title>. <source>Cell</source> <volume>186</volume>, <fpage>1532</fpage>&#x2013;<lpage>1534</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.03.012</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>lncRNA IGKJ2-MALLP2 suppresses LSCC proliferation, migration, invasion, and angiogenesis by sponging miR-1911-3p/p21</article-title>. <source>Cancer Sci.</source> <volume>111</volume>, <fpage>3245</fpage>&#x2013;<lpage>3257</lpage>. <pub-id pub-id-type="doi">10.1111/cas.14559</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>An emerging master inducer and regulator for epithelial-mesenchymal transition and tumor metastasis: extracellular and intracellular ATP and its molecular functions and therapeutic potential</article-title>. <source>Cancer Cell Int.</source> <volume>23</volume>, <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-023-02859-0</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ceranski</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Carre&#xf1;o-Gonzalez</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Ehlers</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Cidre-Aranaz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gr&#xfc;newald</surname>
<given-names>T. G. P.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship</article-title>. <source>Mol. Cancer</source> <volume>22</volume>, <fpage>49</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-023-01750-w</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Risk factors, prognostic factors, and nomograms for distant metastasis in patients with newly diagnosed osteosarcoma: a population-based study</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>12</volume>, <fpage>672024</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2021.672024</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The theory of tumor ecosystem</article-title>. <source>Cancer Commun. (Lond)</source> <volume>42</volume>, <fpage>587</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1002/cac2.12316</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Melatonin suppresses epithelial-to-mesenchymal transition in the MG-63 cell line</article-title>. <source>Mol. Med. Rep.</source> <volume>21</volume>, <fpage>1356</fpage>&#x2013;<lpage>1364</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10902</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conforti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pala</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bagnardi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>De Pas</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Martinetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Viale</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Cancer immunotherapy efficacy and patients&#x27; sex: a systematic review and meta-analysis</article-title>. <source>Lancet Oncol.</source> <volume>19</volume>, <fpage>737</fpage>&#x2013;<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30261-4</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corre</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Verrecchia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crenn</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Redini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Trichet</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The osteosarcoma microenvironment: a complex but targetable ecosystem</article-title>. <source>Cells</source> <volume>9</volume>, <fpage>976</fpage>. <pub-id pub-id-type="doi">10.3390/cells9040976</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daft</surname>
<given-names>P. G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Napierala</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zayzafoon</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanism</article-title>. <source>PLoS One</source> <volume>10</volume>, <fpage>e0121568</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0121568</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Palma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biziato</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Petrova</surname>
<given-names>T. V.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Microenvironmental regulation of tumour angiogenesis</article-title>. <source>Nat. Rev. Cancer</source> <volume>17</volume>, <fpage>457</fpage>&#x2013;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2017.51</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DePeaux</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Delgoffe</surname>
<given-names>G. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Metabolic barriers to cancer immunotherapy</article-title>. <source>Nat. Rev. Immunol.</source> <volume>21</volume>, <fpage>785</fpage>&#x2013;<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-021-00541-y</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The relationship between expression of PD-L1 and HIF-1&#x3b1; in glioma cells under hypoxia</article-title>. <source>J. Hematol. Oncol.</source> <volume>14</volume>, <fpage>92</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-021-01102-5</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Advances in the biological functions and mechanisms of miRNAs in the development of osteosarcoma</article-title>. <source>Technol. Cancer Res. Treat.</source> <volume>21</volume>, <fpage>15330338221117386</fpage>. <pub-id pub-id-type="doi">10.1177/15330338221117386</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The roles of metastasis-related proteins in the development of giant cell tumor of bone, osteosarcoma and Ewing&#x27;s sarcoma</article-title>. <source>Technol. Health Care</source> <volume>29</volume>, <fpage>91</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.3233/THC-218010</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy</article-title>. <source>Biomaterials</source> <volume>269</volume>, <fpage>120642</fpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120642</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>L. K.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities</article-title>. <source>Front. Oncol.</source> <volume>13</volume>, <fpage>1117867</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2023.1117867</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>IGF2BPs as novel m(6)A readers: diverse roles in regulating cancer cell biological functions, hypoxia adaptation, metabolism, and immunosuppressive tumor microenvironment</article-title>. <source>Genes Dis.</source> <volume>11</volume>, <fpage>890</fpage>&#x2013;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1016/j.gendis.2023.06.017</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elanany</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hamdy</surname>
<given-names>N. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer</article-title>. <source>Life Sci.</source> <volume>330</volume>, <fpage>121997</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2023.121997</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Naggar</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Somasekharan</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Negri</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis</article-title>. <source>EMBO Rep.</source> <volume>20</volume>, <fpage>e48375</fpage>. <pub-id pub-id-type="doi">10.15252/embr.201948375</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance</article-title>. <source>J. Bone Oncol.</source> <volume>5</volume>, <fpage>67</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbo.2016.03.001</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fern&#xe1;ndez-Hernando</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Su&#xe1;rez</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis</article-title>. <source>Curr. Opin. Hematol.</source> <volume>27</volume>, <fpage>206</fpage>&#x2013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0000000000000580</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujisaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Futaki</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Epithelial-mesenchymal transition induced in cancer cells by adhesion to type I collagen</article-title>. <source>Int. J. Mol. Sci.</source>, <fpage>24</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24010198</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujiwara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawamoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kawakami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Koterazawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hara</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takemori</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Acquisition of cancer stem cell properties in osteosarcoma cells by defined factors</article-title>. <source>Stem Cell Res. Ther.</source> <volume>11</volume>, <fpage>429</fpage>. <pub-id pub-id-type="doi">10.1186/s13287-020-01944-9</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giordo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wehbe</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Paliogiannis</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Eid</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Mangoni</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Pintus</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Nano-targeting vascular remodeling in cancer: recent developments and future directions</article-title>. <source>Semin. Cancer Biol.</source> <volume>86</volume>, <fpage>784</fpage>&#x2013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2022.03.001</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gkretsi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stylianopoulos</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Cell adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis</article-title>. <source>Front. Oncol.</source> <volume>8</volume>, <fpage>145</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2018.00145</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy</article-title>. <source>Mol. Cancer</source> <volume>22</volume>, <fpage>68</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-023-01769-z</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottfried</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kunz-Schughart</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Ebner</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mueller-Klieser</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hoves</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Andreesen</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Tumor-derived lactic acid modulates dendritic cell activation and antigen expression</article-title>. <source>Blood</source> <volume>107</volume>, <fpage>2013</fpage>&#x2013;<lpage>2021</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2005-05-1795</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>The HIF-1&#x3b1;/CXCR4 pathway supports hypoxia-induced metastasis of human osteosarcoma cells</article-title>. <source>Cancer Lett.</source> <volume>357</volume>, <fpage>254</fpage>&#x2013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2014.11.034</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Paxilitaxel induces apoptosis accompanied by protective autophagy in osteosarcoma cells through hypoxia-inducible factor-1&#x3b1; pathway</article-title>. <source>Mol. Med. Rep.</source> <volume>12</volume>, <fpage>3681</fpage>&#x2013;<lpage>3687</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2015.3860</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haase</surname>
<given-names>V. H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism</article-title>. <source>Hemodial. Int.</source> <volume>21</volume> (<issue>1</issue>), <fpage>S110</fpage>&#x2013;<lpage>s124</lpage>. <pub-id pub-id-type="doi">10.1111/hdi.12567</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamidi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ivaska</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Every step of the way: integrins in cancer progression and metastasis</article-title>. <source>Nat. Rev. Cancer</source> <volume>18</volume>, <fpage>533</fpage>&#x2013;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-018-0038-z</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Long noncoding RNAs in osteosarcoma via various signaling pathways</article-title>. <source>J. Clin. Lab. Anal.</source> <volume>34</volume>, <fpage>e23317</fpage>. <pub-id pub-id-type="doi">10.1002/jcla.23317</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harjunp&#xe4;&#xe4;</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Llort Asens</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guenther</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fagerholm</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>1078</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.01078</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating &#x3b2;-catenin via HIF-1&#x3b1;/BNIP3/LC3B-mediated mitophagy pathway</article-title>. <source>Bioact. Mater</source> <volume>19</volume>, <fpage>690</fpage>&#x2013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1016/j.bioactmat.2022.05.006</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>HIF-1&#x3b1;-Mediated mitophagy determines ZnO nanoparticle-induced human osteosarcoma cell death both <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>. <source>ACS Appl. Mater Interfaces</source> <volume>12</volume>, <fpage>48296</fpage>&#x2013;<lpage>48309</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.0c12139</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Que</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>Anti-Her2 affibody-decorated arsenene nanosheets induce ferroptosis through depleting intracellular GSH to overcome cisplatin resistance</article-title>. <source>J. Nanobiotechnology</source> <volume>21</volume>, <fpage>203</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-023-01963-7</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Fujiki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Holder</surname>
<given-names>J. L.</given-names>
<suffix>Jr.</suffix>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>The transcriptional repressor DEC2 regulates sleep length in mammals</article-title>. <source>Science</source> <volume>325</volume>, <fpage>866</fpage>&#x2013;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1126/science.1174443</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinton</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kirk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Persad</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Regulation of the epithelial to mesenchymal transition in osteosarcoma</article-title>. <source>Biomolecules</source>, <fpage>13</fpage>. <pub-id pub-id-type="doi">10.3390/biom13020398</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hompland</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fjeldbo</surname>
<given-names>C. S.</given-names>
</name>
<name>
<surname>Lyng</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Tumor hypoxia as a barrier in cancer therapy: why levels matter</article-title>. <source>Cancers (Basel)</source> <volume>13</volume>, <fpage>499</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13030499</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>X. K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1&#x3b1; and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells</article-title>. <source>Eur. J. Pharmacol.</source> <volume>874</volume>, <fpage>172961</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.172961</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>34</volume>, <fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-015-0135-8</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>A risk model for prognosis and treatment response prediction in colon adenocarcinoma based on genes associated with the characteristics of the epithelial-mesenchymal transition</article-title>. <source>Int. J. Mol. Sci.</source>, <fpage>24</fpage>. <pub-id pub-id-type="doi">10.3390/ijms241713206</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Dual-responsive nanosystem based on TGF-&#x3b2; blockade and immunogenic chemotherapy for effective chemoimmunotherapy</article-title>. <source>Drug Deliv.</source> <volume>29</volume>, <fpage>1358</fpage>&#x2013;<lpage>1369</lpage>. <pub-id pub-id-type="doi">10.1080/10717544.2022.2069877</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y. H.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume>, <fpage>20</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-1529-9</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hussain</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cherian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Ahirwar</surname>
<given-names>D. K.</given-names>
</name>
<name>
<surname>Ganju</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The roles of stroma-derived chemokine in different stages of cancer metastases</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>598532</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.598532</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ildiz</surname>
<given-names>E. S.</given-names>
</name>
<name>
<surname>Gvozdenovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Aceto</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Travelling under pressure - hypoxia and shear stress in the metastatic journey</article-title>. <source>Clin. Exp. Metastasis</source> <volume>40</volume>, <fpage>375</fpage>&#x2013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1007/s10585-023-10224-8</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Infantino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Santarsiero</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Convertini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Todisco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iacobazzi</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target</article-title>. <source>Int. J. Mol. Sci.</source>, <fpage>22</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22115703</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Itoh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kadomatsu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tanoue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yugami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Endo</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma</article-title>. <source>Oncogene</source> <volume>37</volume>, <fpage>2903</fpage>&#x2013;<lpage>2920</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-018-0160-0</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janiszewska</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Primi</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Izard</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Cell adhesion in cancer: beyond the migration of single cells</article-title>. <source>J. Biol. Chem.</source> <volume>295</volume>, <fpage>2495</fpage>&#x2013;<lpage>2505</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.REV119.007759</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Cracking the code: deciphering the role of the tumor microenvironment in osteosarcoma metastasis</article-title>. <source>Int. Immunopharmacol.</source> <volume>121</volume>, <fpage>110422</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2023.110422</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Aixi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baiwen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zonghuan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Inhibition of hypoxia-inducible factor-1 alpha radiosensitized MG-63 human osteosarcoma cells <italic>in vitro</italic>
</article-title>. <source>Tumori</source> <volume>101</volume>, <fpage>578</fpage>&#x2013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.5301/tj.5000243</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>HIF-1&#x3b1; mediates CXCR4 transcription to activate the AKT/mTOR signaling pathway and augment the viability and migration of activated B cell-like diffuse large B-cell lymphoma cells</article-title>. <source>Mol. Carcinog.</source> <volume>62</volume>, <fpage>676</fpage>&#x2013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1002/mc.23515</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kakkad</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krishnamachary</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pacheco-Torres</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goggins</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bharti</surname>
<given-names>S. K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Molecular and functional imaging insights into the role of hypoxia in cancer aggression</article-title>. <source>Cancer Metastasis Rev.</source> <volume>38</volume>, <fpage>51</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-019-09788-3</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karreman</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Solecki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Berghoff</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Active remodeling of capillary endothelium via cancer cell-derived MMP9 promotes metastatic brain colonization</article-title>. <source>Cancer Res.</source> <volume>83</volume>, <fpage>1299</fpage>&#x2013;<lpage>1314</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-3964</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keremu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maimaitirexiati</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Aila</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xierela</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1&#x3b1;</article-title>. <source>Biosci. Rep.</source> <volume>39</volume>. <pub-id pub-id-type="doi">10.1042/BSR20170080</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Kerbel</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa</article-title>. <source>Nat. Rev. Clin. Oncol.</source> <volume>15</volume>, <fpage>310</fpage>&#x2013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1038/nrclinonc.2018.9</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khojastehnezhad</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Seyedi</surname>
<given-names>S. M. R.</given-names>
</name>
<name>
<surname>Raoufi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Asoodeh</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Association of hypoxia-inducible factor 1 expressions with prognosis role as a survival prognostic biomarker in the patients with osteosarcoma: a meta-analysis</article-title>. <source>Expert Rev. Mol. Diagn</source> <volume>22</volume>, <fpage>1099</fpage>&#x2013;<lpage>1106</lpage>. <pub-id pub-id-type="doi">10.1080/14737159.2022.2157719</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kikuchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yoshioka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Prieto-Vila</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ochiya</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Involvement of extracellular vesicles in vascular-related functions in cancer progression and metastasis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>20</volume>, <fpage>2584</fpage>. <pub-id pub-id-type="doi">10.3390/ijms20102584</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koh</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Spivak-Kroizman</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Venturini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Welsh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>D. L.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha</article-title>. <source>Mol. Cancer Ther.</source> <volume>7</volume>, <fpage>90</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0463</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuo</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Lien</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment</article-title>. <source>Cancer Immunol. Immunother.</source> <volume>72</volume>, <fpage>351</fpage>&#x2013;<lpage>369</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-022-03255-9</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kushwaha</surname>
<given-names>P. P.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Emerging role of migration and invasion enhancer 1 (MIEN1) in cancer progression and metastasis</article-title>. <source>Front. Oncol.</source> <volume>9</volume>, <fpage>868</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.00868</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Quercetin inhibits cell migration and invasion in human osteosarcoma cells</article-title>. <source>Cell Physiol. Biochem.</source> <volume>43</volume>, <fpage>553</fpage>&#x2013;<lpage>567</lpage>. <pub-id pub-id-type="doi">10.1159/000480528</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Jee</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>A group of novel HIF-1&#x3b1; inhibitors, glyceollins, blocks HIF-1&#x3b1; synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding</article-title>. <source>J. Cell Physiol.</source> <volume>230</volume>, <fpage>853</fpage>&#x2013;<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.24813</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z. G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>H. P.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway</article-title>. <source>Cancer Lett.</source> <volume>376</volume>, <fpage>188</fpage>&#x2013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.03.023</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ci</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis</article-title>. <source>Nat. Commun.</source> <volume>12</volume>, <fpage>2773</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-021-22674-3</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Dimmitt</surname>
<given-names>N. H.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>P. H.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins</article-title>. <source>Elife</source> <volume>12</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.7554/elife.83768</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bickler</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L. F.</given-names>
</name>
<name>
<surname>Altschuler</surname>
<given-names>S. J.</given-names>
</name>
</person-group> (<year>2023b</year>). <article-title>Searching for molecular hypoxia sensors among oxygen-dependent enzymes</article-title>. <source>Elife</source> <volume>12</volume>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.7554/elife.87705</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>HIF-1&#x3b1;-induced upregulation of lncRNA UCA1 promotes cell growth in osteosarcoma by inactivating the PTEN/AKT signaling pathway</article-title>. <source>Oncol. Rep.</source> <volume>39</volume>, <fpage>1072</fpage>&#x2013;<lpage>1080</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6182</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Anti-tumor effects of triptolide on angiogenesis and cell apoptosis in osteosarcoma cells by inducing autophagy via repressing Wnt/&#x3b2;-Catenin signaling</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>496</volume>, <fpage>443</fpage>&#x2013;<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2018.01.052</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M. Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023c</year>). <article-title>HIF-1&#x3b1; inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization</article-title>. <source>Biomed. Pharmacother.</source> <volume>161</volume>, <fpage>114423</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114423</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. F.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Hypoxia and the tumor microenvironment</article-title>. <source>Technol. Cancer Res. Treat.</source> <volume>20</volume>, <fpage>15330338211036304</fpage>. <pub-id pub-id-type="doi">10.1177/15330338211036304</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Q. L.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021c</year>). <article-title>CircRNA_103801 accelerates proliferation of osteosarcoma cells by sponging miR-338-3p and regulating HIF-1/Rap1/PI3K-Akt pathway</article-title>. <source>J. Biol. Regul. Homeost. Agents</source> <volume>35</volume>, <fpage>1021</fpage>&#x2013;<lpage>1028</lpage>. <pub-id pub-id-type="doi">10.23812/20-725-A</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy</article-title>. <source>MedComm</source> <volume>2023</volume> (<issue>4</issue>), <fpage>e350</fpage>. <pub-id pub-id-type="doi">10.1002/mco2.350</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liberti</surname>
<given-names>M. V.</given-names>
</name>
<name>
<surname>Locasale</surname>
<given-names>J. W.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The Warburg effect: how does it benefit cancer cells?</article-title> <source>Trends Biochem. Sci.</source> <volume>41</volume>, <fpage>211</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2015.12.001</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1&#x3b1;</article-title>. <source>Hum. Cell</source> <volume>32</volume>, <fpage>64</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1007/s13577-018-0224-z</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>MicroRNA-20b downregulates HIF-1&#x3b1; and inhibits the proliferation and invasion of osteosarcoma cells</article-title>. <source>Oncol. Res.</source> <volume>23</volume>, <fpage>257</fpage>&#x2013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.3727/096504016X14562725373752</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q. L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H. N.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z. G.</given-names>
</name>
</person-group> (<year>2021a</year>). <article-title>Epigenetic regulation of epithelial to mesenchymal transition in the cancer metastatic cascade: implications for cancer therapy</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>657546</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.657546</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rothzerg</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Current research progress in targeted anti-angiogenesis therapy for osteosarcoma</article-title>. <source>Cell Prolif.</source> <volume>54</volume>, <fpage>e13102</fpage>. <pub-id pub-id-type="doi">10.1111/cpr.13102</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside</article-title>. <source>Exp. Hematol. Oncol.</source> <volume>11</volume>, <fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/s40164-022-00352-4</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. D.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>HIF-1&#x3b1;-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2</article-title>. <source>Sci. Rep.</source> <volume>12</volume>, <fpage>10398</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-13660-w</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Suo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>HIF-1&#x3b1; silencing inhibits the growth of osteosarcoma cells by inducing apoptosis</article-title>. <source>Ann. Clin. Lab. Sci.</source> <volume>46</volume>, <fpage>140</fpage>&#x2013;<lpage>146</lpage>.</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L. Z.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>W. S. T.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Targeting hypoxia-inducible factor-1-mediated metastasis for cancer therapy</article-title>. <source>Antioxid. Redox Signal</source> <volume>34</volume>, <fpage>1484</fpage>&#x2013;<lpage>1497</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2019.7935</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magae</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kuwahara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Nakajima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y. C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>4-O-methylascochlorin stabilizes hypoxia-inducible factor-1 in a manner different from hydroxylase inhibition by iron chelating or substrate competition</article-title>. <source>Biosci. Biotechnol. Biochem.</source> <volume>83</volume>, <fpage>2244</fpage>&#x2013;<lpage>2248</lpage>. <pub-id pub-id-type="doi">10.1080/09168451.2019.1651626</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meazza</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Scanagatta</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Metastatic osteosarcoma: a challenging multidisciplinary treatment</article-title>. <source>Expert Rev. Anticancer Ther.</source> <volume>16</volume>, <fpage>543</fpage>&#x2013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1586/14737140.2016.1168697</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohamed</surname>
<given-names>O. A. A.</given-names>
</name>
<name>
<surname>Tesen</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Hany</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sherif</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abdelwahab</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Elnaggar</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The role of hypoxia on prostate cancer progression and metastasis</article-title>. <source>Mol. Biol. Rep.</source> <volume>50</volume>, <fpage>3873</fpage>&#x2013;<lpage>3884</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-023-08251-5</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Multhoff</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vaupel</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Hypoxia compromises anti-cancer immune responses</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1232</volume>, <fpage>131</fpage>&#x2013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-030-34461-0_18</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nangaku</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eckardt</surname>
<given-names>K. U.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Hypoxia and the HIF system in kidney disease</article-title>. <source>J. Mol. Med. Berl.</source> <volume>85</volume>, <fpage>1325</fpage>&#x2013;<lpage>1330</lpage>. <pub-id pub-id-type="doi">10.1007/s00109-007-0278-y</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neophytou</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Panagi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stylianopoulos</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Papageorgis</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The role of tumor microenvironment in cancer metastasis: molecular mechanisms and therapeutic opportunities</article-title>. <source>Cancers (Basel)</source> <volume>13</volume>, <fpage>2053</fpage>. <pub-id pub-id-type="doi">10.3390/cancers13092053</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieto</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R. Y.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Thiery</surname>
<given-names>J. P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>EMT: 2016</article-title>. <source>Cell</source> <volume>166</volume>, <fpage>21</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.06.028</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Espinosa-Cotton</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H. F.</given-names>
</name>
<name>
<surname>Monette</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>N. V.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting tumor vasculature to improve antitumor activity of T cells armed <italic>ex vivo</italic> with T cell engaging bispecific antibody</article-title>. <source>J. Immunother. Cancer</source>, <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1136/JITC-2023-006680</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peinado</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matei</surname>
<given-names>I. R.</given-names>
</name>
<name>
<surname>Costa-Silva</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hoshino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Pre-metastatic niches: organ-specific homes for metastases</article-title>. <source>Nat. Rev. Cancer</source> <volume>17</volume>, <fpage>302</fpage>&#x2013;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1038/nrc.2017.6</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phan</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies</article-title>. <source>Cancer Biol. Med.</source> <volume>11</volume>, <fpage>1</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.7497/j.issn.2095-3941.2014.01.001</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pih&#xe1;n</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carreras-Sureda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hetz</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>BCL-2 family: integrating stress responses at the ER to control cell demise</article-title>. <source>Cell Death Differ.</source> <volume>24</volume>, <fpage>1478</fpage>&#x2013;<lpage>1487</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.82</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rastogi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aldosary</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Saeedan</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Ansari</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaithwas</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>NF-&#x3ba;B mediated regulation of tumor cell proliferation in hypoxic microenvironment</article-title>. <source>Front. Pharmacol.</source> <volume>14</volume>, <fpage>1108915</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1108915</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ravenna</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Salvatori</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>HIF3&#x3b1;: the little we know</article-title>. <source>Febs J.</source> <volume>283</volume>, <fpage>993</fpage>&#x2013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1111/febs.13572</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>HIF-1&#x3b1; induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21</article-title>. <source>Biomed. Pharmacother.</source> <volume>117</volume>, <fpage>109104</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2019.109104</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rickel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Molecular genetics of osteosarcoma</article-title>. <source>Bone</source> <volume>102</volume>, <fpage>69</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.bone.2016.10.017</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Mechanisms of cell adhesion molecules in endocrine-related cancers: a concise outlook</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>13</volume>, <fpage>865436</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.865436</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabharwal</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Dudley</surname>
<given-names>V. J.</given-names>
</name>
<name>
<surname>Landwerlin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schumacker</surname>
<given-names>P. T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>HH<sub>2</sub>O<sub>2</sub> transit through the mitochondrial intermembrane space promotes tumor cell growth in&#xa0;vitro and in&#xa0;vivo</article-title>. <source>J. Biol. Chem.</source> <volume>299</volume>, <fpage>104624</fpage>. <pub-id pub-id-type="doi">10.1016/j.jbc.2023.104624</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Hypoxia-inducible factors in physiology and medicine</article-title>. <source>Cell</source> <volume>148</volume>, <fpage>399</fpage>&#x2013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.01.021</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>A nuclear factor induced by hypoxia via <italic>de novo</italic> protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation</article-title>. <source>Mol. Cell Biol.</source> <volume>12</volume>, <fpage>5447</fpage>&#x2013;<lpage>5454</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.12.12.5447</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Activation of PGRN/MAPK axis stimulated by the hypoxia-conditioned mesenchymal stem cell-derived HIF-1&#x3b1; facilitates osteosarcoma progression</article-title>. <source>Exp. Cell Res.</source> <volume>421</volume>, <fpage>113373</fpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2022.113373</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Qiao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Positive feedback regulation of circular RNA Hsa_circ_0000566 and HIF-1&#x3b1; promotes osteosarcoma progression and glycolysis metabolism</article-title>. <source>Aging Dis.</source> <volume>14</volume>, <fpage>529</fpage>&#x2013;<lpage>547</lpage>. <pub-id pub-id-type="doi">10.14336/AD.2022.0826</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Hypoxia-inducible factor-1&#x3b1; inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models</article-title>. <source>Anticancer Drugs</source> <volume>33</volume>, <fpage>587</fpage>&#x2013;<lpage>594</lpage>. <pub-id pub-id-type="doi">10.1097/CAD.0000000000001294</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoaib</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Irudayaraj</surname>
<given-names>J. M. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Osteosarcoma mechanobiology and therapeutic targets</article-title>. <source>Br. J. Pharmacol.</source> <volume>179</volume>, <fpage>201</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1111/bph.15713</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Samanta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bishayee</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression</article-title>. <source>Biomolecules</source> <volume>10</volume>, <fpage>1561</fpage>. <pub-id pub-id-type="doi">10.3390/biom10111561</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smeland</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bielack</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hogendoorn</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Krailo</surname>
<given-names>M. D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort</article-title>. <source>Eur. J. Cancer</source> <volume>109</volume>, <fpage>36</fpage>&#x2013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2018.11.027</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sukumar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Crompton</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Inhibiting glycolytic metabolism enhances CD8&#x2b; T cell memory and antitumor function</article-title>. <source>J. Clin. Invest.</source> <volume>123</volume>, <fpage>4479</fpage>&#x2013;<lpage>4488</lpage>. <pub-id pub-id-type="doi">10.1172/JCI69589</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>B. Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z. W.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Metabolism of reactive oxygen species in osteosarcoma and potential treatment applications</article-title>. <source>Cells</source> <volume>9</volume>, <fpage>87</fpage>. <pub-id pub-id-type="doi">10.3390/cells9010087</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Resveratrol abrogates the effects of hypoxia on cell proliferation, invasion and EMT in osteosarcoma cells through downregulation of the HIF-1&#x3b1; protein</article-title>. <source>Mol. Med. Rep.</source> <volume>11</volume>, <fpage>1975</fpage>&#x2013;<lpage>1981</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2014.2913</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>lncRNA nuclear-enriched abundant transcript 1 promotes cell proliferation and invasion by targeting miR-186-5p/HIF-1&#x3b1; in osteosarcoma</article-title>. <source>J. Cell Biochem.</source> <volume>120</volume>, <fpage>6502</fpage>&#x2013;<lpage>6514</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.27941</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>MT1-MMP as a key regulator of metastasis</article-title>. <source>Cells</source>, <fpage>12</fpage>. <pub-id pub-id-type="doi">10.3390/cells12172187</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shuai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>CYB561D2 up-regulation activates STAT3 to induce immunosuppression and aggression in gliomas</article-title>. <source>J. Transl. Med.</source> <volume>19</volume>, <fpage>338</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-021-02987-z</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tarin</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Role of the host stroma in cancer and its therapeutic significance</article-title>. <source>Cancer Metastasis Rev.</source> <volume>32</volume>, <fpage>553</fpage>&#x2013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-013-9438-4</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Th&#xfc;ring</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schwietzer</surname>
<given-names>Y. A.</given-names>
</name>
<name>
<surname>Ebnet</surname>
<given-names>K.</given-names>
</name>
</person-group>
<collab>TMIGD1</collab> (<year>2023</year>). <article-title>TMIGD1: emerging functions of a tumor supressor and adhesion receptor</article-title>. <source>Oncogene</source> <volume>42</volume>, <fpage>1777</fpage>&#x2013;<lpage>1785</lpage>. <pub-id pub-id-type="doi">10.1038/s41388-023-02696-5</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nice</surname>
<given-names>E. C.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment</article-title>. <source>Bone Res.</source> <volume>11</volume>, <fpage>11</fpage>. <pub-id pub-id-type="doi">10.1038/s41413-023-00246-z</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Lien</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C. H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>CCL4 stimulates cell migration in human osteosarcoma via the mir-3927-3p/integrin &#x3b1;v&#x3b2;3 Axis</article-title>. <source>Int. J. Mol. Sci.</source>, <fpage>22</fpage>. <pub-id pub-id-type="doi">10.3390/ijms222312737</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Tzeng</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S. W.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma</article-title>. <source>Cell Death Dis.</source> <volume>8</volume>, <fpage>e2750</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2016.421</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tuomisto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Solano</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sirni&#xf6;</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>V&#xe4;yrynen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Guillermo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>M&#xe4;kinen</surname>
<given-names>M. J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>HIF-1&#x3b1; expression and high microvessel density are characteristic features in serrated colorectal cancer</article-title>. <source>Virchows Arch.</source> <volume>469</volume>, <fpage>395</fpage>&#x2013;<lpage>404</lpage>. <pub-id pub-id-type="doi">10.1007/s00428-016-1988-8</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tzeng</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y. J.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity</article-title>. <source>Int. J. Mol. Sci.</source>, <fpage>24</fpage>. <pub-id pub-id-type="doi">10.3390/ijms24054422</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vailas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Syllaios</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashemaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sotiropoulou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schizas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Papalampros</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Irreversible electroporation and sarcomas: where do we stand?</article-title> <source>J. buon</source> <volume>24</volume>, <fpage>1354</fpage>&#x2013;<lpage>1359</lpage>.</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valastyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Tumor metastasis: molecular insights and evolving paradigms</article-title>. <source>Cell</source> <volume>147</volume>, <fpage>275</fpage>&#x2013;<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.09.024</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>V&#xe9;gran</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Boidot</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Michiels</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sonveaux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Feron</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-&#x3ba;B/IL-8 pathway that drives tumor angiogenesis</article-title>. <source>Cancer Res.</source> <volume>71</volume>, <fpage>2550</fpage>&#x2013;<lpage>2560</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2828</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vito</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>El-Sayes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mossman</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Hypoxia-driven immune escape in the tumor microenvironment</article-title>. <source>Cells</source> <volume>9</volume>, <fpage>992</fpage>. <pub-id pub-id-type="doi">10.3390/cells9040992</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Fallois</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kosyna</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Mandl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Landesman</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dunst</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Depping</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Selinexor decreases HIF-1&#x3b1; via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity</article-title>. <source>J. Cancer Res. Clin. Oncol.</source> <volume>147</volume>, <fpage>2025</fpage>&#x2013;<lpage>2033</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-021-03626-2</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1</article-title>. <source>Cancer Biol. Ther.</source> <volume>20</volume>, <fpage>999</fpage>&#x2013;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1080/15384047.2019.1591675</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Semenza</surname>
<given-names>G. L.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia</article-title>. <source>J. Biol. Chem.</source> <volume>268</volume>, <fpage>21513</fpage>&#x2013;<lpage>21518</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(20)80571-7</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2023a</year>). <article-title>Synergistic chemoimmunotherapy augmentation via sequential nanocomposite hydrogel-mediated reprogramming of cancer-associated fibroblasts in osteosarcoma</article-title>. <source>Adv. Mater</source> <volume>2023</volume>, <fpage>e2309591</fpage>. <pub-id pub-id-type="doi">10.1002/adma.202309591</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment</article-title>. <source>Carcinogenesis</source> <volume>36</volume>, <fpage>104</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgu218</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019b</year>). <article-title>Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma</article-title>. <source>Am. J. Transl. Res.</source> <volume>11</volume>, <fpage>6341</fpage>&#x2013;<lpage>6355</lpage>.</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>SENP1/HIF-1&#x3b1; feedback loop modulates hypoxia-induced cell proliferation, invasion, and EMT in human osteosarcoma cells</article-title>. <source>J. Cell Biochem.</source> <volume>119</volume>, <fpage>1819</fpage>&#x2013;<lpage>1826</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.26342</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2023b</year>). <article-title>TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer</article-title>. <source>J. Nanobiotechnology</source> <volume>21</volume>, <fpage>440</fpage>. <pub-id pub-id-type="doi">10.1186/s12951-023-02203-8</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watson</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Vignali</surname>
<given-names>P. D. A.</given-names>
</name>
<name>
<surname>Mullett</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Overacre-Delgoffe</surname>
<given-names>A. E.</given-names>
</name>
<name>
<surname>Peralta</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Grebinoski</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Metabolic support of tumour-infiltrating regulatory T cells by lactic acid</article-title>. <source>Nature</source> <volume>591</volume>, <fpage>645</fpage>&#x2013;<lpage>651</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-03045-2</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>X. X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X. S.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>TRAF6 inhibits colorectal cancer metastasis through regulating selective autophagic CTNNB1/&#x3b2;-catenin degradation and is targeted for GSK3B/GSK3&#x3b2;-mediated phosphorylation and degradation</article-title>. <source>Autophagy</source> <volume>15</volume>, <fpage>1506</fpage>&#x2013;<lpage>1522</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2019.1586250</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Effects of anoxic prognostic model on immune microenvironment in pancreatic cancer</article-title>. <source>Sci. Rep.</source> <volume>13</volume>, <fpage>9104</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-36413-9</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Reciprocal regulation between the circadian clock and hypoxia signaling at the genome level in mammals</article-title>. <source>Cell Metab.</source> <volume>25</volume>, <fpage>73</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.009</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>miR-186 functions as a tumor suppressor in osteosarcoma cells by suppressing the malignant phenotype and aerobic glycolysis</article-title>. <source>Oncol. Rep.</source> <volume>39</volume>, <fpage>2703</fpage>&#x2013;<lpage>2710</lpage>. <pub-id pub-id-type="doi">10.3892/or.2018.6394</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>BPA exposure enhances the metastatic aggression of ovarian cancer through the ER&#x3b1;/AKT/mTOR/HIF-1&#x3b1; signaling axis</article-title>. <source>Food Chem. Toxicol.</source> <volume>176</volume>, <fpage>113792</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2023.113792</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>TGF-&#x3b2; protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1&#x3b1; dependent manner</article-title>. <source>BMC Cancer</source> <volume>21</volume>, <fpage>1200</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-021-08954-7</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1&#x3b1; pathway</article-title>. <source>Oncol. Rep.</source> <volume>44</volume>, <fpage>103</fpage>&#x2013;<lpage>114</lpage>. <pub-id pub-id-type="doi">10.3892/or.2020.7611</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>microRNA-216b enhances cisplatin-induced apoptosis in osteosarcoma MG63 and SaOS-2 cells by binding to JMJD2C and regulating the HIF1&#x3b1;/HES1 signaling axis</article-title>. <source>J. Exp. Clin. Cancer Res.</source> <volume>39</volume>, <fpage>201</fpage>. <pub-id pub-id-type="doi">10.1186/s13046-020-01670-3</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>1-Bromopropane-induced apoptosis in OVCAR-3 cells via oxidative stress and inactivation of Nrf2</article-title>. <source>Int. J. Oncol.</source> <volume>37</volume>, <fpage>59</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1177/0748233720979427</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021b</year>). <article-title>Effects of hypoxia on proliferation and apoptosis of osteosarcoma cells</article-title>. <source>Anticancer Res.</source> <volume>41</volume>, <fpage>4781</fpage>&#x2013;<lpage>4787</lpage>. <pub-id pub-id-type="doi">10.21873/anticanres.15293</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2021c</year>). <article-title>Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies</article-title>. <source>Cancer Cell Int.</source> <volume>21</volume>, <fpage>589</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-021-02299-8</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>BCLAF1-induced HIF-1&#x3b1; accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex</article-title>. <source>Cancer Immunol. Immunother.</source> <volume>72</volume>, <fpage>4279</fpage>&#x2013;<lpage>4292</lpage>. <pub-id pub-id-type="doi">10.1007/s00262-023-03563-8</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1&#x3b1; via miR-143-5p</article-title>. <source>Cell Death Dis.</source> <volume>10</volume>, <fpage>280</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-1509-1</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zahedipour</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bolourinezhad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sahebkar</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The multifaceted therapeutic mechanisms of curcumin in osteosarcoma: state-of-the-art</article-title>. <source>J. Oncol.</source> <volume>2021</volume>, <fpage>3006853</fpage>. <pub-id pub-id-type="doi">10.1155/2021/3006853</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanconato</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cordenonsi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Piccolo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yap and</surname>
<given-names>T. A. Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>YAP and TAZ: a signalling hub of the tumour microenvironment</article-title>. <source>Nat. Rev. Cancer</source> <volume>19</volume>, <fpage>454</fpage>&#x2013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-019-0168-y</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Ginsenoside Rg3 inhibits HIF-1&#x3b1; and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways</article-title>. <source>Int. J. Clin. Exp. Pathol.</source> <volume>7</volume>, <fpage>2172</fpage>&#x2013;<lpage>2178</lpage>.</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zepeda-Enr&#xed;quez</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Silva-C&#xe1;zares</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Camarillo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Novel insights into circular RNAs in metastasis in breast cancer: an update</article-title>. <source>Noncoding RNA</source>, <fpage>9</fpage>. <pub-id pub-id-type="doi">10.3390/NCRNA9050055</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maggio</surname>
<given-names>D. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017e</year>). <article-title>Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha</article-title>. <source>Oncotarget</source> <volume>8</volume>, <fpage>56110</fpage>&#x2013;<lpage>56125</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.18125</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Que</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2017b</year>). <article-title>MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1&#x3b1; protein</article-title>. <source>Oncotarget</source> <volume>8</volume>, <fpage>2342</fpage>&#x2013;<lpage>2355</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13672</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hypoxia stimulates the migration and invasion of osteosarcoma via up-regulating the NUSAP1 expression</article-title>. <source>Open Med. (Wars)</source> <volume>16</volume>, <fpage>1083</fpage>&#x2013;<lpage>1089</lpage>. <pub-id pub-id-type="doi">10.1515/med-2020-0180</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kastrenopoulou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Larrouture</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Athanasou</surname>
<given-names>N. A.</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Angiopoietin-like 4 promotes osteosarcoma cell proliferation and migration and stimulates osteoclastogenesis</article-title>. <source>BMC Cancer</source> <volume>18</volume>, <fpage>536</fpage>. <pub-id pub-id-type="doi">10.1186/s12885-018-4468-5</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X. D.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>2017c</year>). <article-title>Effects of siRNA-mediated HIF-1&#x3b1; gene silencing on angiogenesis in osteosarcoma</article-title>. <source>Pak J. Med. Sci.</source> <volume>33</volume>, <fpage>341</fpage>&#x2013;<lpage>346</lpage>. <pub-id pub-id-type="doi">10.12669/pjms.332.12587</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1&#x3b1; and autophagy in human osteosarcoma</article-title>. <source>Oncotarget</source> <volume>8</volume>, <fpage>91134</fpage>&#x2013;<lpage>91149</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.19845</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Characterization of tumour microenvironment reprogramming reveals invasion in epithelial ovarian carcinoma</article-title>. <source>J. Ovarian Res.</source> <volume>16</volume>, <fpage>200</fpage>. <pub-id pub-id-type="doi">10.1186/s13048-023-01270-7</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Inhibiting GIT1 reduces the growth, invasion, and angiogenesis of osteosarcoma</article-title>. <source>Cancer Manag. Res.</source> <volume>10</volume>, <fpage>6445</fpage>&#x2013;<lpage>6455</lpage>. <pub-id pub-id-type="doi">10.2147/CMAR.S181066</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>GRM4 inhibits the proliferation, migration, and invasion of human osteosarcoma cells through interaction with CBX4</article-title>. <source>Biosci. Biotechnol. Biochem.</source> <volume>84</volume>, <fpage>279</fpage>&#x2013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1080/09168451.2019.1673147</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z. C.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>S. C.</given-names>
</name>
<etal/>
</person-group> (<year>2017d</year>). <article-title>Targeting the long noncoding RNA MALAT1 blocks the pro-angiogenic effects of osteosarcoma and suppresses tumour growth</article-title>. <source>Int. J. Biol. Sci.</source> <volume>13</volume>, <fpage>1398</fpage>&#x2013;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.22249</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>LINK-A lncRNA functions in the metastasis of osteosarcoma by upregulating HIF1&#x3b1;</article-title>. <source>Oncol. Lett.</source> <volume>17</volume>, <fpage>5005</fpage>&#x2013;<lpage>5011</lpage>. <pub-id pub-id-type="doi">10.3892/ol.2019.10177</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma</article-title>. <source>Int. J. Clin. Oncol.</source> <volume>20</volume>, <fpage>1233</fpage>&#x2013;<lpage>1243</lpage>. <pub-id pub-id-type="doi">10.1007/s10147-015-0848-x</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>HIF-1&#x3b1; signaling: essential roles in tumorigenesis and implications in targeted therapies</article-title>. <source>Genes Dis.</source> <volume>11</volume>, <fpage>234</fpage>&#x2013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.gendis.2023.02.039</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse</article-title>. <source>J. Hematol. Oncol.</source> <volume>11</volume>, <fpage>16</fpage>. <pub-id pub-id-type="doi">10.1186/s13045-018-0560-1</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>G. Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q. H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>S. X.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Dioscin induces osteosarcoma cell apoptosis by upregulating ROS-mediated P38 MAPK signaling</article-title>. <source>Drug Dev. Res.</source> <volume>84</volume>, <fpage>25</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/ddr.22009</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Expression of programmed death 1 is correlated with progression of osteosarcoma</article-title>. <source>Apmis</source> <volume>123</volume>, <fpage>102</fpage>&#x2013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1111/apm.12311</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Single-cell and bulk RNA sequencing reveals Anoikis related genes to guide prognosis and immunotherapy in osteosarcoma</article-title>. <source>Sci. Rep.</source> <volume>13</volume>, <fpage>20203</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-023-47367-3</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Sauchinone inhibits hypoxia-induced invasion and epithelial-mesenchymal transition in osteosarcoma cells via inactivation of the sonic hedgehog pathway</article-title>. <source>J. Recept Signal Transduct. Res.</source> <volume>42</volume>, <fpage>173</fpage>&#x2013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1080/10799893.2021.1881556</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z. N.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>L. J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>New advances in circulating tumor cell-mediated metastasis of breast cancer (Review)</article-title>. <source>Mol. Clin. Oncol.</source> <volume>19</volume>, <fpage>71</fpage>. <pub-id pub-id-type="doi">10.3892/mco.2023.2667</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>MicroRNA-33b inhibits the proliferation and migration of osteosarcoma cells via targeting hypoxia-inducible factor-1&#x3b1;</article-title>. <source>Oncol. Res.</source> <volume>25</volume>, <fpage>397</fpage>&#x2013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.3727/096504016X14743337535446</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>